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ANTIGEN PRESENTATION:  
INFLUENCE OF CELL TYPE AND ROUTE OF ANTIGEN UPTAKE 
 
Alice O. Kamphorst, Ph.D. 
The Rockefeller University 2011 
 
Dendritic cells (DCs), which maintain tolerance and orchestrate T cell immune responses, 
comprise a heterogeneous group of cells. For example, in the steady state, murine spleen 
contains pre-DC-derived CD8+DEC-205+ and CD8-DCIR2+ conventional DCs. To 
examine antigen processing and presentation in vivo, antigens were specifically targeted 
to CD8+ and CD8- DCs using chimeric monoclonal antibodies. We find that CD8- DCs 
are better than CD8- DCs for presentation of exogenous antigens onto major 
histocompatibility complex (MHC) class II molecules due to cell intrinsic differences. 
 
DCs are responsible for initiating T cell responses. However, during inflammation, 
monocytes become activated and acquire some DC-like features such as expression of 
CD11c, MHCII and co-stimulatory molecules, yet their role in T cell activation is still a 
matter of investigation. Cells similar to DCs can also be produced in vitro by culturing 
monocytes with granulocyte-macrophage colony-stimulating factor (GM-CSF) or bone 
marrow progenitors (pre-DCs) with fms-related tyrosine kinase ligand (FL). Although 
each of these cell types can present antigen, the relative efficiency of processing and 
presentation after antigen capture by different routes has not yet been systematically 
compared. To this end we administered OVA to various conventional DCs and activated 
monocytes by receptor-mediated endocytosis, pinocytosis or phagocytosis and measured 
antigen uptake and presentation to MHCI and MHCII restricted T cells. We find that 
CD8- DCs are more efficient than any other types of antigen presenting cells tested in 
terms of presenting antigen to MHCII restricted CD4+ T cells, irrespective of the route of 
antigen capture or maturation status. In contrast, both subsets of splenic DCs are equally 
efficient at cross-presenting antigens to CD8+ T cells. All DCs and activated monocytes 
cross-presented antigens delivered by receptor-mediated endocytosis and pinocytosis, 
albeit with different efficiencies. However monocyte-derived cells differ from DCs in 
that they are several orders of magnitude less efficient in presenting antigens captured by 
phagocytosis. DCs derived from pre-DCs are unique, processing and presenting antigens 
efficiently irrespective of the route of antigen capture. Our observations have significant 
implications for understating initiation of immune responses and vaccination strategies 
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Dendritic Cells (DCs) are professional antigen presenting cells, necessary for maintaining 
tolerance and initiating immune responses. The primary function of DCs is to present 
antigens to T cells, while controlling and modulating T cell activation with cytokines and 
co-stimulatory molecules. DCs are very efficient at antigen uptake: they continuously 
internalize soluble antigens and express numerous receptors that bind and internalize 
pathogens. Captured antigens are processed into peptides for both MHC class II (MHCII) 
and MHC class I (MHCI) presentation (cross-presentation). Different subsets of DCs 
have been identified, but until recently, few functional differences between these subsets 
were defined.   
 
In this thesis, I compare the antigen presentation efficiency of different DC subsets 
(splenic CD8+ and CD8- DCs) for both MHCII presentation and cross-presentation. In 
vivo experiments were performed targeting antigen to DC receptors. These studies were 
supplemented with ex-vivo antigen administration through receptor-mediated 
endocytosis, phagocytosis and pinocytosis. I also analyzed the antigen presentation 
efficiency of activated monocytes that appear during inflammation. Furthermore, I 
compared splenic DCs to other antigen presenting cells (APCs) that can be differentiated 
in vitro. For the several different APCs analyzed, I address the impact of the route of 
antigen uptake and of cell intrinsic factors on antigen presentation efficiency. 
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Historical Perspective of Antigen Presentation 
Unlike B cells, T cells require accessory cells for antigen recognition and activation 
(Waldron et al., 1973). Seminal studies in 1974 showed that to recognize antigen, T cells 
must share the same major histocompatibility complex (MHC) as accessory cells 
(Zinkernagel and Doherty, 1974).  
 
The need for antigen processing by accessory cells was proposed because interactions 
between accessory cells and T cells only began 20-60 minutes after antigen 
internalization. During this processing time, active metabolism but not protein synthesis 
was necessary (Ziegler and Unanue, 1981). 
 
 A few years later, it was demonstrated that peptides are generated during processing, and 
bind to MHC molecules, allowing T cells to recognize antigen and become activated 
(Babbitt et al., 1985; Shimonkevitz et al., 1983). By the mid 1980’s, the general 
principals of antigen processing and presentation for T cell activation were in place. 
Since then, many fundamental studies added to the complexity of this process, but many 
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Dendritic Cells 
DCs were first recognized for their unique dendritic morphology (Steinman and Cohn, 
1973). A few years later, DCs were characterized as potent stimulators of the mixed 
leukocyte reaction (Steinman and Witmer, 1978) and effector T cell responses 
(Nussenzweig et al., 1980; Steinman, 2007), orders of magnitude better than 
macrophages, the best accessory cells known at that time. 
 
DCs can be found in lymphoid and non-lymphoid tissues. Although no single unique 
feature can distinguish all DCs, they are characterized by expression of CD11c (integrin 
αX) and high levels of MHCII. DCs consist of a heterogeneous population that can be 
divided into several subsets. Several aspects concerning subset grouping and defined 
functional specializations remain unresolved (Heath et al., 2004). Yet, recent data from 
ontogeny and gene expression support the current division of DC subsets in lymphoid 
organs (Edelson et al., 2010; Liu et al., 2009; Robbins et al., 2008). 
 
Like all other immune cells, DCs originate from hematopoietic stem cells. They have a 
short half-life: spleen and lymph node DCs are replaced by progenitors from the blood 
within 10 to 14 days (Liu et al., 2007). Although DCs are closely related to monocytes 
and macrophages, they develop from committed progenitors that diverge in the bone 
marrow (Liu et al., 2009). The lineage split occurs when macrophage-and-DC progenitors 
(MDPs) (Fogg et al., 2006; Varol et al., 2007) differentiate into either monocytes or 
common-DC progenitors (CDPs) (Naik et al., 2007; Onai et al., 2007). CDPs no longer 
give rise to monocytes and macrophages, and they further differentiate into pre-DCs, 
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losing the potential to produce plasmacytoid DCs (Liu et al., 2009). Pre-DCs leave the 
bone marrow, circulate in the blood and seed lymphoid (Liu et al., 2009) and non-
lymphoid organs (Bogunovic et al., 2009; Ginhoux et al., 2009; Varol et al., 2009). DCs 
divide in response to fms-related tyrosine kinase ligand (FL) (Liu et al., 2007; Waskow et 
al., 2008) and differentiate into subsets of conventional DCs. In lymphoid organs, DCs 
are incorporated into networks of cells and present antigen to migrating T cells (Lindquist 
et al., 2004; Liu et al., 2009).  
 
Plasmacytoid dendritic cells (pDCs) are very distinct from other DCs, known as 
conventional DCs (cDCs). pDCs are B220+, CD11cint and produce large amounts of type 
I interferon upon CpG DNA or viral exposure (Gilliet et al., 2008; Liu, 2005). pDCs are 
long-lived, finish their developmental program in the bone marrow, and do not show a 
dendritic-like morphology. Their role in antigen presentation is still debated (Bar-On and 
Jung, 2010), and pDCs will not be discussed further in this thesis. 
 
In murine spleen, conventional DCs can be divided into two major subsets based on the 
expression of CD8α. The CD8+ subset is also positive for DEC-205. The CD8- DC subset 
includes a major CD4+ (CD11b+ and DCIR2+) population and a minor CD4- (DN, double 
negative) population. CD8- DCs localize in the marginal zone and the red pulp of the 
spleen, while CD8+ DCs reside in the T cell area (Ardavin, 2003; Dudziak et al., 2007). 
In C57BL/6 mice the DCIR2+ population represents more than 50% of splenic DCs. Both 
cDC subsets, CD8+ and CD8-, derive directly from pre-DCs and are usually called 
resident DCs (Liu et al., 2009). 
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In addition to resident DCs, lymph nodes also contain CD11cint and MHCIIhi migratory 
DCs (Henri et al., 2001). DCs migrate from tissues to lymph nodes via lymphatics in a 
CCR7-dependent manner (Ohl et al., 2004). Migratory DCs can be further divided into 
different subsets. For example, the subsets can be based on the expression of CD11b, 
CD207 (langerin) and CD103 (integrin αE) (Henri et al., 2010; Nagao et al., 2009). 
Lymph nodes contain different populations of migratory DCs depending on the tissue 
drained.  
 
The division of non-lymphoid organ DCs into subsets is more complex and only recently 
supported by functional and developmental data. Increasing evidence support a 
correspondence between CD11b-CD103+ DCs in non-lymphoid organs and CD8+ DCs in 
lymphoid organs. For example, both CD11b-CD103+ dermal DCs and CD8+ DCs excel in 
cross-presentation of cell-associated antigens (Bedoui et al., 2009) and are 
developmentally dependent on the basic leucine zipper transcription factor, ATF-like 3 
(Batf3) (Hildner et al., 2008). Likewise, CD11b-CD103+ DCs in kidneys, lung and liver 
rely on the same cytokine (FL) and transcription factors (Id2 and IRF8) as CD8+ splenic 
DCs (Ginhoux et al., 2009). However, unlike splenic DCs, tissue-resident 
CD11b+CD103- DCs have a partial developmental dependence on M-CSF-R 
(macrophage colony stimulating factor receptor). Furthermore, although pre-DCs can 
give rise to both CD11b+CD103- and CD11b-CD103+ DCs in liver and kidneys, 
monocytes can also differentiate into CD11b+CD103- DCs. Therefore, CD11b+CD103- 
DCs might constitute a heterogeneous population (Ginhoux et al., 2009).  
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The gut lamina propria contains pre-DC-derived CD11b+CD103+ DCs that support the 
development of regulatory T cells, and also monocyte-derived CD11c+CD103- CX3CR1+ 
cells that have a prominent role during inflammation (Bogunovic et al., 2009; Varol et al., 
2009). Interestingly, lamina propria CD11b+ CD103+ DCs differ from CD8+ splenic DCs 
and CD11b-CD103+ DCs found in Peyer’s patches, in that the former are not dependent 
on IRF8 (Ginhoux et al., 2009) and Batf3 (Edelson et al., 2010). 
 
During inflammation or infection, the distribution of DCs in lymphoid organs changes, 
and new subsets can appear (Serbina et al., 2008). Under these conditions, monocytes can 
differentiate into cells with DC-like features such as CD11c and MHCII expression 
(Geissmann et al., 2003; Leon et al., 2007; Naik et al., 2006; Randolph et al., 1999). For 
example, during Listeria infection monocytes differentiate in the spleen into tumor 
necrosis factor (TNF) and inducible nitric oxide synthase (iNOS) producing CD11c+ cells 
(tip-DCs) (Serbina et al., 2003). Nonetheless a prominent role of monocyte-derived DC-
like cells in antigen presentation has not been established, and instead innate functions 
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In Vitro Differentiation of Dendritic Cells from Precursors 
Cells with many DC features can be derived from monocytes cultured with cytokines, 
such as granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-4 (Inaba et 
al., 1992a; Sallusto and Lanzavecchia, 1994). GM-CSF was initially found to promote the 
survival of murine Langerhans cells (Witmer-Pack et al., 1987) and later shown to 
promote the development of CD11c+ cells from blood (Inaba et al., 1992b) and bone 
marrow progenitors (Inaba et al., 1992a).  
 
GM-CSF monocyte-derived DCs (GM-DCs) are widely used as a dendritic cell source, 
both in basic murine studies (Mellman and Steinman, 2001; Trombetta and Mellman, 
2005) and in human clinical studies (Steinman and Dhodapkar, 2001). However, it was 
recently established that in steady state most conventional DCs are GM-CSF-
independent, FL-dependent and derived from pre-DCs (Liu et al., 2009; Waskow et al., 
2008). Also, GM-DCs seem to be more related to activated monocytes as measured by 
production of inflammatory mediators, such as TNF-α and nitric oxide (Xu et al., 2007), 
and global gene expression profile (Robbins et al., 2008). 
 
GM-CSF deficient mice have normal hematopoietic development except for functional 
defects on alveolar macrophages (Stanley et al., 1994) and a lack of CD103+ dermal DCs 
(King et al., 2010). GM-CSF administration in mice results in increased circulating 
neutrophils and cycling of peritoneal macrophages but no overt changes in DC numbers. 
In humans, GM-CSF administration increases blood monocyte numbers (Hamilton, 
2002).  
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On the other hand, FL administration induces a dramatic increase in DC numbers in mice 
(Maraskovsky et al., 1996) and also increases circulating DCs in humans (Maraskovsky 
et al., 2000). All DC progenitors, from short-term hematopoietic cells to pre-DCs, are 
positive for Flk2, the receptor for FL (Schmid et al., 2010). Accordingly, FL deficient 
mice show a decrease in DC numbers - as well as in hematopoietic progenitors, B cells 
and NK cells (McKenna et al., 2000).  
 
Murine bone marrow progenitors cultured with FL differentiate into CD11c+ cells (FL-
DCs) (Brasel et al., 2000). FL-DCs are heterogeneous and can be separated into 3 
subpopulations based on expression of CD11c, B220, CD24 and SIRPα. From the 
transcription profile and cell-associated antigen presentation assays, it was suggested that 
CD11c+B220+ cells correspond to pDCs, CD11c+B220-CD24hi correspond to CD8+ 
splenic DCs and CD11c+B220-SIPRαhi correspond to CD8- splenic DCs (Naik et al., 
2005). Although further functional studies are lacking, using FL to differentiate DCs 
appears to generate cells that strongly resemble conventional steady state DCs. 
 
 
Dendritic Cell Function 
T cells recognize antigen when the T cell receptor (TCR) binds MHC-peptide complexes: 
CD4+ T cells bind MHCII-peptide complexes, and CD8+ T cells bind MHCI-peptide 
complexes. TCR binding to cognate MHC-peptide complex initiates a signaling cascade 
that triggers calcium flux and changes in gene transcription on the T cells. Upon antigen 
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recognition, T cells up-regulate CD69 expression and enter cell cycle. Several factors 
modulate T cell activation and cause T cells to differentiate into distinct classes of 
effector cells: cytokines, density of MHC-peptide complexes; affinity between the TCR 
and MHC-peptide complexes; and co-stimulatory molecules that stabilize the 
immunological synapse or deliver additional signals. 
 
In the steady state, DCs capture antigens and present them to T cells, ensuring tolerance 
by promoting regulatory T cell development or deletion and anergy of self-reactive T 
cells (Steinman et al., 2003). DCs can promote deletion or anergy of T cells, when 
presenting antigens in the steady state (Hawiger et al., 2001; Hawiger et al., 2004; Miller 
et al., 1998). One mechanism proposed is antigen presentation without proper T cell co-
stimulation, e.g. ligation of CTLA-4 and PD-1, instead of CD28 (Probst et al., 2005). 
DCs can also promote the differentiation and survival of regulatory T cells (Darrasse-Jeze 
et al., 2009; Kretschmer et al., 2005; Yamazaki et al., 2008). Lamina propria DCs induce 
regulatory T cell conversion by tumor growth factor (TGF)-β and retinoic acid dependent 
mechanisms (Coombes et al., 2007; Sun et al., 2007).  
 
Importantly, DCs have an innate sensing function, reacting to potential pathogens and 
changing the context in which they present antigens to T cells in order to initiate 
adaptative immune responses. Hence DCs regulate both the induction of immunological 
tolerance and immunity.  
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DCs express pathogen-recognition receptors such as Toll-like receptors (TLRs), 
nucleotide oligomerization domain (NOD)-like receptors, retinoic acid inducible gene 
(RIG)-I-like receptors, as well as lectins (Joffre et al., 2009). Ligation of TLRs, for 
example, leads to signaling cascades involving the intracellular adaptors MyD88 
(myeloid differentiation primary response gene 88) and/or TRIF (TIR domain-containing 
adapter-inducing interferon-β) that activate transcription factors involved in inflammation 
(e.g. NFκB, AP-1, IRF3). The concerted action of these transcription factors is 
responsible for the expression of innate response genes (pro-inflammatory cytokines and 
chemokines). TLR ligation also increases membrane expression of molecules that 
optimize T cell activation such as MHC-peptide complexes and co-stimulatory molecules 
(B7 family members). These phenotypic changes on DCs, from a naïve state to an 
activated state, are termed maturation. Maturation can also be induced by inflammatory 
cytokines such as TNFα, IL-1β or IL-6, or by interaction with T cells through CD40-
ligation (Caux et al., 1994; Gallucci and Matzinger, 2001). Antigen presentation by 
mature DCs leads to T cell activation into effector cells (Guermonprez et al., 2002). 
 
Distinct effector CD4+ T cells secrete different cytokines that impact upon host resistance 
and immunopathology. The class of effector T cell responses is dictated both by the DC 
subset and by the stimuli that triggered DC maturation (Pulendran et al., 2008). Upon 
TLR ligation, splenic CD8+ DCs produce IL-12 and express CD70 (Soares et al., 2007), 
activating T cells to produce IFN-γ (Th1 responses). Splenic CD8- DCs elicit Th2 
polarized T cell differentiation (IL-4, IL-5 and IL-13 production) (Maldonado-Lopez et 
al., 1999; Maldonado-Lopez et al., 2001; Soares et al., 2007). Nonetheless, splenic CD8- 
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DCs can also induce Th1 responses, when IL-12 is present (e.g. produced by CD8+ DCs) 
(Soares et al., 2007) or by expression of Delta 4 Notch-like ligand (Skokos and 
Nussenzweig, 2007). DCs respond to environmental cues, secreting different cytokines 
and expressing distinct co-stimulatory molecules that modulate T cell differentiation. For 
example, epithelial cells can produce thymic stromal lymphopoietin (TSLP) that inhibits 
IL-12 production and induces OX-40L expression on DCs, favoring Th2 responses (Ito et 
al., 2005; Soumelis et al., 2002; Taylor et al., 2009). Alternatively, factors secreted by 
parasites can also directly modulate DCs to induce Th2 responses (Everts et al., 2009; 




Dendritic Cells and Lectins 
Dendritic cells express several different lectins and lectin-like receptors (carbohydrate-
binding proteins) (Dudziak et al., 2007; Robinson et al., 2006). Many of these lectins are 
members of the Ca2+-dependent C-type lectin family that function in cell adhesion (cell-
cell contacts and migration), pathogen recognition and antigen uptake (Cambi and 
Figdor, 2003). For example, DC-SIGN has been implicated in DC migration, adhesion to 
T cells, (Geijtenbeek et al., 2000; van Kooyk and Geijtenbeek, 2002), as well as binding 
to human immunodeficiency virus and other pathogens (Cambi et al., 2003; Engering et 
al., 2002; Geijtenbeek and van Kooyk, 2003; van Die et al., 2003). 
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C-type lectins can be classified in groups based on their molecular structure. Type VI 
lectins are type I transmembrane proteins (intracellular C-terminus) with large 
extracellular domains containing a membrane distal cysteine-rich domain, followed by a 
fibronectin type II domain and 8 to 10 C-type lectin like domains. Members of this family 
include the phospholipase A2 receptor, the (macrophage mannose receptor) MMR and 
DEC-205. Type II lectins have a single extracellular C-terminal C-type lectin-like 
domains and include DC-SIGN, Langerin, BDCA-2, Dectin and DCIR (Figdor et al., 
2002).  
 
Unlike TLRs, which have a defined and conserved intracellular signaling cascade, lectins 
differ greatly in their intracellular motifs and no common adaptors have been described. 
Interestingly, crosslinking of BDCA-2 suppresses TLR-induced type-I interferon 
production by pDCs (Dzionek et al., 2001). Other lectins can also suppress TLR signaling 
(Robinson et al., 2006). On the contrary, engagement of Dectin-1 (Brown, 2006; 
Leibundgut-Landmann et al., 2008) or CLEC9A (Caminschi et al., 2008) triggers 
signaling cascades that promote DC activation and consequently T-cell immune 
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Antigen Targeting to Dendritic Cells 
Antigen delivery to DCs in vivo was pioneered using antibodies that bind to DEC-205, a 
multilectin endocytic receptor that is highly expressed by CD8+ DCs (Bonifaz et al., 
2002; Boscardin et al., 2006; Hawiger et al., 2001; Hawiger et al., 2004; Trumpfheller et 
al., 2006). Recently, a similar strategy of antigen targeting to the CD8- DC subset was 
developed with anti-DCIR2 antibodies (Dudziak et al., 2007; Nussenzweig et al., 1982).  
 
Targeting antigen to DCs increases presentation to T cells by 100-fold (Hawiger et al., 
2001). Antigen targeting to DEC-205 or DCIR-2 in the steady state leads to the induction 
of immunological tolerance, whereas, in the presence of maturation stimuli, such as anti-
CD40, it results in immunity (Bonifaz et al., 2002; Dudziak et al., 2007; Hawiger et al., 
2001; Steinman et al., 2003). 
 
Antigen delivery to several other molecules expressed by DCs also promotes antigen 
presentation to T cells. Examples include Dectin-1 (Carter et al., 2006b), Dectin-2 (Carter 
et al., 2006a), DNGR-1 (Sancho et al., 2008), langerin (Idoyaga et al., 2008) and MHCII 
(Dickgreber et al., 2009), among others. 
 
DEC-205 
The monoclonal anti-DEC-205 antibody (rat IgG2a, NLDC-145) was first described in 
1986, recognizing a 145Kd antigen expressed by “non-lymphoid DCs” (Kraal et al., 
1986). It was re-named DEC-205 due to its rectified molecular weight of 205 Kd and 
expression on dendritic and epithelial cells (Jiang et al., 1995; Swiggard et al., 1995).  
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Anti-DEC-205 (anti-DEC) antibodies are quickly endocytosed in clathrin-coated vesicles 
and delivered to an intracellular compartment where antigen processing for antigen 
presentation to T cells ensues (Jiang et al., 1995). When DEC-205 and the MMR are 
compared, a distinct intracellular distribution is observed. DEC-205 has higher co-
localization with LAMP-1 and MHCII positive compartments. In addition, DEC-205 is 
superior to MMR in mediating antigen presentation to CD4+ T cells. Using a 
heterologous system, the differences between DEC-205 and the MMR were ascribed to 
an acidic amino acid cluster (EDE) on the DEC-205 cytoplasmic tail (Mahnke et al., 
2000). 
 
In humans, DEC-205 is expressed on monocyte-derived DCs as well as on DCs in the T-
cell areas of spleen and lymph nodes (Pack et al., 2008). Antigen targeting to DEC-205 
on human monocyte-derived DCs also results in antigen presentation to both CD8+ 
(Bozzacco et al., 2007) and CD4+ T cells (Gurer et al., 2008). 
 
DCIR-2 
The 33D1 antibody (rat IgG2b, anti-DCIR2) was the first DC-specific antibody generated 
(Nussenzweig et al., 1982), enabling specific depletion of DCs and definitively 
demonstrating DCs’ prominent role as accessory cells for the mixed leukocyte reaction 
(Steinman et al., 1983) and in T-cell dependent antibody production (Inaba et al., 1983). 
The combination of 33D1 and anti-DEC-205 staining, among other markers, revealed 
that there were two different kinds of splenic DCs (Crowley et al., 1989).  
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Through a combination of gene array and candidate gene approaches, DCIR2 (Clec4a4) 
was identified as the antigen for the 33D1 antibody (Dudziak et al., 2007). DCIR is an 
abbreviation for dendritic cell inhibitory molecule. The family consists of 4 members: 
DCIR1, DCIR2, DCIR3, DCIR4 (Flornes et al., 2004). Both DCIR1 and DCIR2 contain 
an inhibitory ITIM motive in the intracellular domain. Most studies involving murine 
DCIR are referring to DCIR1 (Clec4a2) (Bates et al., 1999; Fujikado et al., 2008; 
Kanazawa et al., 2004), and no further studies with DCIR2 have been reported so far. In 
humans, by sequence analysis, just one inhibitory C-type lectin gene exists and is 




DCs possess several mechanisms to sense and sample the environment. DCs acquire 
antigens through pinocytosis, phagocytosis or receptor mediated endocytosis.  
 
Pinocytosis (or macropinocytosis) is a constitutive process in DCs and can be induced, 
e.g. by growth-factors in other cell types. It is initiated by membrane ruffling (actin-rich 
extensions of the plasma membrane) that collapse and internalize extracellular material. 
The internalized material (usually fluid) and membrane form large vesicles (greater than 
0.2 µm in diameter) that follow a similar intracellular pathway as other endocytic vesicles 
(Kerr and Teasdale, 2009).  
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Phagocytosis is also an actin-dependent process, but it involves local membrane 
activation for the uptake of large (greater than 0.5 µm) particulate matter. It is an 
evolutionary conserved immune-related process, specific to a few cell types such as 
macrophages, neutrophils and DCs. Particle opsonization by antibodies or complement 
fixation enhance phagocytosis (Greenberg and Grinstein, 2002). DCs, particularly the 
CD8+ subset, are very efficient in phagocytosis of apoptotic cells (Iyoda et al., 2002). 
 
In addition, DCs display complement, scavenger and Fc-receptors, as well as C-type 
lectins that can bind pathogens and other antigens. Receptor-mediated endocytosis 
typically occurs from coated pits, by recruitment of dynamin and adaptor proteins to form 
clathrin-coated vesicles. Caveolin containing invaginations or clathrin/caveolin 
independent internalization may also occur is some specific situations, but the 
contribution of these processes to antigen presentation remains unexplored (Conner and 
Schmid, 2003; Mellman, 1996). 
 
DC activation induces an initial increase in pinocytosis (West et al., 2004), followed by a 
gradual decrease over 1-2 days (Sallusto et al., 1995). Inhibition of antigen capture by 
mature DCs is attributed to inactivation of Cdc42, a Rho GTPase family member that 
promotes actin polymerization (Garrett et al., 2000). Receptor-mediated endocytosis is 
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Upon internalization, antigens are sorted and delivered into different compartments 
depending on adaptor proteins recruited during the internalization process (Lakadamyali 
et al., 2006). Early endosomes are mildly acidic (pH of ≈6.0) and rely on the small 
GTPase Rab5, early endosome antigen 1 (EEA1) and phosphoinositide 3-kinase for their 
formation and function. As a consequence of the low pH, some ligands dissociate from 
their receptors and mix with internalized solutes. Membranes pinch off from early 
endosomes and fuse back to the plasma membrane, or go to Rab4 and Rab11 positive 
endosomes (recycling endosomes). Thus membrane proteins that do not have specific 
motifs for lysosomal delivery are usually diverted back to the plasma membrane. Proteins 
containing tyrosine-based and dileucine-based amino acid motifs, or ubiquitylation of 
cytoplasmic domains, are directed to a degradative pathway; they go to acidic late 
endosomes/multivesicular bodies (Rab7 positive) and lysosomes (pH<5, where 
catabolism occurs) (Bonifacino, 2003; Maxfield and McGraw, 2004; Saftig and 
Klumperman, 2009). Alternatively, some proteins can engage in a retrograde transport 
pathway, from either early or late endosomes, that results in sorting into the Golgi 
complex. For example, in order to gain access to the Golgi and the ER, toxins exploit 
retrograde transport mechanisms (Johannes and Popoff, 2008).  
 
Endosomes are a very flexible and complex network, where several intermediate stages 
exist: vesicles exchange contents gradually and “mature” over time. Therefore the 
division into early and late endosome is only a simplification of the process. 
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Antigen Processing and Presentation 
Constitutive MHCII expression characterizes professional antigen presenting cells: DCs, 
B cells, macrophages and thymic epithelial cells. After internalization, exogenous 
antigens reach endosomal compartments where they are digested into peptides that can 
associate with MHCII molecules.  
 
MHCII molecules are guided to endosomes by the invariant chain (Ii). In the endoplasmic 
reticulum (ER), MHCII molecules (heterodimers of α-chain and β-chain) associate with 
Ii trimers, forming nonamers (αβIi)3. This association blocks the peptide-binding groove 
on MHCII molecules and guides the complex through the Golgi apparatus into 
endosomes. Alternatively, Ii-MHC complexes go transiently to the plasma membrane and 
are internalized back into endosomes. The acidic environment of endosomes triggers Ii 
degradation by cathepsins, leaving only a small portion that blocks the peptide-binding 
groove (CLIP, Ii derived MHC class II-associated invariant chain peptide).  CLIP is 
displaced when MHCII molecules interact with catalyst HLA-DM/H2-M (in 
humans/mice), allowing binding of antigenic peptides present in endosomal 
compartments. MHCII-peptide complexes then travel to the plasma membrane to mediate 
antigen presentation (Jensen, 2007; Landsverk et al., 2009; Trombetta and Mellman, 
2005).  
 
Intracellular antigens can also be delivered to lysosomes and have access to MHCII 
presentation in a process denominated autophagy (Munz, 2010; Paludan et al., 2005). 
Autophagy as means to promote MHCII presentation of intracellular antigens is an 
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important physiological process in thymic epithelium with great impact in CD4+ T cell 
tolerance (Nedjic et al., 2008), and it also occurs constitutively in a myriad of other cell 
types, including DCs (Schmid et al., 2007). 
 
Unlike MHCII, all nucleated cells express MHCI molecules. Classical MHCI 
presentation occurs after degradation of ubiquitylated intracellular proteins by the 
proteasome, generated for example from the catabolism of endogenous proteins. Peptides 
generated by the proteasome are degraded by cytoplasmic peptidases or shuttled into the 
ER by the TAP complex (transporter associated with antigen processing). In the ER, 
calnexin assists MHCI heavy chain assembly with the invariant β2-microglobulin, and 
peptides can be loaded onto nascent MHCI molecules with the assistance of chaperones 
(tapasin, calreticulin). ER amino peptidases (ERAP) are responsible for the final 
trimming of peptides for MHCI loading. MHCI-peptide complexes leave the ER and 
travel through the Golgi complex to the plasma membrane (Jensen, 2007).  
 
Extracellular antigens can also be loaded onto MHC class I molecules in a process called 
cross-presentation. The cellular mechanisms responsible for cross-presentation are not 
resolved and at least 3 different intracellular routes have been proposed: (1) cytosolic, 
TAP-dependent pathway in which antigens (or peptides) escape from endosomes, into the 
cytoplasm, where they are degraded by the proteasome or directly shuttled into the ER by 
TAP; (2) retrograde-like pathway in which ER components fuse with endosomes during 
the internalization process; (3) vacuolar, TAP-independent pathway in which endosomes 
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containing exogenous proteins and peptides can fuse with endosomes containing 
recycling MHCI molecules (Guermonprez et al., 2002; Jensen, 2007). 
 
The current view is that MHCII presentation of exogenous antigens is more robust than 
cross-presentation, since it can occur in either early and recycling endosomes (with low 
proteolytic activity/neutral-low pH), where newly generated peptides associate with 
recycling MHCII molecules, or occur in late endosomes (high proteolytic activity/low 
pH), where antigenic peptides displace CLIP, and are loaded into nascent MHCII 
molecules. In opposition to MHCII presentation, cross-presentation is favored when the 
antigen is retained in early and recycling endosomes (Belizaire and Unanue, 2009; Savina 
et al., 2006). 
 
The mechanism of antigen uptake determines the recruitment of adaptor proteins and thus 
the nature of the intracellular compartment reached. Distinct intracellular compartments 
have different pH and proteases, affecting the generation of peptides. Also, as described 
above, MHC molecules traffic between different compartments, and peptide loading 
occurs in a few favorable environments. Thus the intracellular compartments reached by 
the antigens profoundly impact antigen processing and presentation. Ovalbumin (OVA) 
internalization through the MMR in GM-DCs, results in antigen retainment in early 
endosomes and exclusive cross-presentation. OVA internalization, through scavenger 
receptors in bone marrow derived macrophages, results only in late endosomal delivery 
and MHCII presentation (Burgdorf et al., 2007). Internalized soluble OVA can escape to 
the cytosol where it undergoes proteasomal processing and peptides reach MHCI 
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molecules by a TAP-dependent pathway. In contrast, internalized soluble hen egg 
lysozyme (HEL) does not reach the cytoplasm; conversely, it travels to late endosomes 
compartments, and no HEL cross-presentation can be detected. Nonetheless, HEL 
entrapped in liposomes, with early endosomal release, is processed and loaded into 
MHCI within early endosomes (vacuolar pathway) (Amigorena and Savina, 2010; 
Belizaire and Unanue, 2009) 
 
Cell intrinsic factors (expression of proteases, ATP pumps and even route of MHC 
molecules) can also impact antigen presentation. When compared to macrophages, GM-
DCs have low levels of lysosomal proteases (Delamarre et al., 2005; Lennon-Dumenil et 
al., 2002), which correlate with higher formation of MHC-peptide complexes (Delamarre 
et al., 2006). Immature GM-DCs control protein degradation by limiting V-ATPase 
assembly, thus preventing endosomal acidification (Trombetta et al., 2003). In addition 
the recruitment of the NADPH oxidase NOX2 into endosomes prevents acidification, and 
NOX2 deficient DCs are less efficient at cross-presentation (Savina et al., 2006).  
 
CD8+ DCs are superior at cross-presenting antigens after ingestion of dead cells or during 
viral infection (Belz et al., 2005; Hildner et al., 2008; Jirmo et al., 2009), and cell-
intrinsic mechanisms have been proposed by various groups (Amigorena and Savina, 
2010). NOX2 is specifically recruited in CD8+ DCs phagosomes, but not in CD8- DCs, 
and NOX2 recruitment is responsible to avoid phagosomal acidification and therefore 
favors antigen cross-presentation (Savina et al., 2009). Cytochrome C administration to 
mice is toxic to CD8+ DCs, but not CD8- DCs, suggesting that CD8+ DCs have unique 
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mechanisms to transport exogenous antigens into the cytosol (Lin et al., 2008). However 
definitive data showing the mechanism responsible for CD8+ DC superiority at cross-
presentation is still lacking. 
 
Most studies on antigen presentation by DCs were performed with GM-DCs. Although 
extremely valuable, they are restricted to one particular cell type. In addition, GM-DCs 
are closer to monocytes than DCs in both mRNA expression profile (Robbins et al., 
2008) and phenotype (Xu et al., 2007). Several subsets of DCs can be identified in vivo, 
and their relative contribution to antigen presentation is a matter of intense investigation. 
Here I compare MHCI and MHCII antigen presentation by resting or activated spleen 
DCs (CD8+ and CD8- subsets) after in vivo or in vitro antigen delivery. I initiated this 
study by delivering antigens using recombinant antibodies to DC receptors. I also 
compared receptor-mediated endocytosis to pinocytosis and phagocytosis. To 
complement my work, I analyzed the antigen presentation efficiency of activated 
monocytes, GM-DCs and FL-DCs, as well as B cell blasts. 
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Chapter 2 
 
Materials and Methods 
 
Mice 
C57BL/6, B10.BR, C3H/HeJ and Balb/c were purchased from Jackson Laboratory. 
Unless stated otherwise, C57BL/6 mice were used. TCR transgenic OTII and OTI mice, 
specific for OVA peptide in the context of IAb and H2Kb, respectively, were bred to 
C57BL/6 CD45.1 mice. Transgenic TCR specific for H2Kd-SYVPSAEQI (peptide from 
Plasmodium yoelii circumporozoite protein)(Sano et al., 2001) and CD11c-hDEC 
(Dudziak et al., 2007) mice; B1-8hi Immunoglobulin heavy chain knock-in (Shih et al., 
2002) mice; DEC-205 deficient (Guo et al., 2000) and GM-CSF receptor-β deficient 
(Robb et al., 1995) mice were maintained and bred at the Rockefeller University. 6-10-
week-old mice were used in experiments. All experiments were performed in accordance 
with NIH guidelines and approved by The Rockefeller University Animal Care and Use 
Committee. 
 
Production of chimeric antibodies and other antigens 
The following chimeric antibodies were produced: anti-mouse-DEC-OVA, anti-DCIR2-
OVA, anti-human-DEC-OVA, Iso-OVA, anti-mouse-DEC-HEL, anti-DCIR2-HEL, anti-
human-DEC-HEL, Iso-HEL, anti-mouse-DEC-CSpep (peptide SYVPSAEQI from 
Plasmodium yoelii circumporozoite protein), anti-DCIR2-CSpep, Iso-CSpep, anti-mouse-
DEC-CSf (circumsporozoite protein from Plasmodium falciparum) and anti-DCIR2-CSf. 
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Chimeric antibodies were expressed by transient transfection of 293T cells (ATCC) and 
purified with Protein G (GE Healthcare) as described (Hawiger et al., 2001; Tiller et al., 
2008).  
 
OVA (Grade V, Sigma) was decontaminated from LPS by multiple rounds of extraction 
with triton-X 114 (Sigma) (Aida and Pabst, 1990) and dialysed extensively. NP (4-
hydroxy-3-nitrophenil, Biosearch) and Biotin (Invitrogen) were conjugated to OVA 
according to manufacturers’ instructions. All antigens were run in SDS-PAGE, tested for 
LPS contamination (Fisher-Cambrex) and decontaminated by triton-X 114 extraction 
when necessary (above 0.005 EU/ µg).  
 
OVA was adsorbed to 2 µM red beads (Polysciences) according to the manufacturer’s 
protocol. Briefly, 0.5 ml of 2.5% suspension of beads was resuspended in 0.1 M borate 
buffer pH 8.5 and incubated overnight with 500 µg of OVA at 4°C. Alternatively, to 
obtain 25% OVA-beads, beads were incubated overnight with 125 µg of OVA and 375 
µg of keyhole limpet hemocyanin (KLH, Sigma). Unbound protein was washed away 
extensively, and OVA-adsorbed beads were resuspended in 1 ml PBS. Coupling was 
confirmed by flow-cytometry with anti-OVA antibodies (rabbit, Cappel) followed by 
anti-rabbit-Cy5 (mouse, Jackson Immunoresearch). 
 
Antibodies and flow cytometry analysis 
The following antibodies were purchased from either BD or eBioscience: CD3 (145-
2C11), CD4 (L3T4), CD8 (53-6.7), CD11b (M1/70), CD11c (N418, HL3), CD16 and 
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CD32/Fc block (2.4G2), CD19 (MB19-1 or eBio1D3), CD24/HSA (M1/69), 
CD45R/B220 (RA3-6B2), CD45.1 (A20), CD45.2 (104), CD69 (H1.2F3), CD86 (GL1), 
CD115/CSF-1R (AFS98), CD135/Flk-2/Flt3 (A2F10), CD172α/SIRPα (P84), 
mouseCD205/mDEC-205 (205yefta), humanCD205 /hDEC-205 (Mg38), DCIR2 (33D1), 
Fas/CD95 (Jo2), GL7, H2Kb (AF6-88.5), I-Ek (14-4-4S), Ly6C (AL-21 or HK1.4), Ly6G 
(1A8), MHCII (AF6-120.1 or M5/114.15.2), NK1.1 (PK136), Ter-119, Thy1.1 (OX-7), 
Vα2 (B20.1) and anti-mouse IgG1 (A85-1). Streptavidin-PE and –PE-Cy5.5 were from 
eBioscience. Streptavidin APC was from BD. Streptavidin Pacific Blue and DAPI were 
from Invitrogen. Anti-OVA was from Cappel. Anti-mouse IgG, anti-mouse IgG1, anti-rat 
and anti-rabbit were from Jackson Immunoresearch. Anti-rat-PE was from Santa Cruz. 
Antibodies to DEC-205 (NLDC-145), DCIR2 (331D1, DC), IAk-HEL (Aw1.18.14) 
(Dadaglio et al., 1997) and Plasmodium falciparum circumporozoite protein (2A10) 
(Hollingdale et al., 1984), were purified from hybridomas and labeled with biotin, Alexa 
Fluor 488 or Alexa Fluor 647 (Molecular Probes). Isotype controls rat IgG2a and rat 
IgG2b biotin, Alexa Fluor 488 and Alexa Fluor 647 were from Molecular Probes.  
 
Cell suspensions were incubated in PBS 2% FCS (fetal calf serum, Gibco) with purified 
Fc block and surface staining was performed with indicated antibodies for 20-60 minutes 
on ice. Data was acquired on Calibur or LSR-II (BD). Analysis was performed using 




                 25
Immunofluorescence  
Splenic section were fixed and stained as described previously (Lindquist et al., 2004). 
Briefly, spleens from C57BL/6 mice were fixed in PBS with 4% paraformaldehyde and 
10% sucrose; cryoprotected in 30% sucrose; embedded in optimum cutting temperature 
compound and frozen at -80°C. Frozen tissues were sectioned (10-20 µm thickness) on a 
microtome and fixed in acetone. All incubations were done in a humidified chamber. 
Sections were blocked in 5% BSA in HBSS. The primary antibodies were IgD-Alexa 
Fluor 568 (eBioscience/in house labeling with Invitrogen kit), CD3-FITC (BD) and 
chimeric anti-DCIR2-CSf, anti-DEC-CSf or Iso-CSf. Secondary antibody was anti-
CSfalciparum-Alexa Fluor 647 (in house production). Sections were mounted in 
Fluoromount-G (Southern Biotech). Confocal images were acquired on a Zeiss LSM 510 
system equipped with 488, 543 and 633 nm excitation lines at The Rockefeller University 
Bio-Imaging Facility. Images were obtained with a 20x Plan Apochromat (NA 0.75) 
objective. Images were processed in Adobe Photoshop. 
 
Detection of chimeric antibodies by flow cytometry 
DCIR2 binding is calcium dependent, so EDTA was omitted in all steps. Anti-
mouseDEC and anti-DCIR2 chimeric antibodies have a mouse IgG1 constant region. For 
extracellular detection, splenocytes were stained 15 min on ice with anti-mouse IgG1 
FITC (A85-1, BD) or anti-mouse IgG1 Cy5 (goat polyclonal, Jackson Immunoresearch) 
in PBS 1% BSA 0.05% azide. Cells were washed and fixed (Cytofix/Cytoperm, BD). For 
total chimeric antibody detection, splenocytes were stained, after fixation, with anti-
mouse IgG1 FITC or Cy5 in Perm/Wash (BD). For intracellular chimeric antibody 
                 26
detection, extracellular signal was blocked with saturating amounts of unlabeled anti-
mouse IgG1 and after washing, cells were fixed and stained with anti-mouse IgG1 FITC 
or Cy5 in Perm/Wash. Cells were subsequently stained with antibodies to CD11c, CD8α 
and CD4 to identify DC populations. 
 
In some experiments, rat monoclonal anti-DEC (NLDC) or anti-DCIR2 (33D1) were 
used. Antibody detection was with anti-rat Cy5 (mouse F(ab’)2, Jackson 
Immunoresearch) with similar protocol as described above. 
 
Detection of chimeric antibodies by Western blot 
Splenic DCs were enriched with anti-CD11c beads (Miltenyi) according to 
manufacturer’s instructions. Enriched DCs were incubated on ice with chimeric anti-
DEC-CSf or anti-DCIR2-CSf at 5 µg/ml, and excess antibodies were removed by 
washing. DCs were either kept on ice or incubated for 10-180 minutes at 37°C in 
complete RPMI media (RPMI 1640 supplemented with 10% FCS, 10 mM HEPES, 2 mM 
L-Glutamine, Antibiotic/AntiMycotic, 1 mM Sodium Pyruvate and 53 µM 2-ME, all 
from Gibco). To remove extracellular antibodies, DCs were washed with RPMI buffered 
to pH 3.6 with citric acid. 2x106 DCs were lysed in 1% NP-40, 150 mM NaCl, 10mM 
TrisHCl pH8 buffer containing EDTA-free protease-inhibitor cocktail (Roche), incubated 
on ice for 30 min, and debris spun out at 14,000 rpm, 4°C. Samples were separated on 4-
12% acrylamide Bis/Tris/SDS gels (Invitrogen), transferred to PVDF membranes 
(Millipore) and blotted with biotinilated anti-CS falciparum antibodies (in house 
production) followed by steptavidin-HRP (Jackson Immunoresearch). Membranes were 
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blotted with anti-β-actin (Sigma) followed by anti-mouse-HRP (Jackson 
Immunoresearch) as loading control. Western blots were developed using enhanced 
chemiluminescent substrate (ECL, Pierce).  
 
In vivo antigen administration 
Mice were injected intraperitoneally (i.p.) or intravenously (i.v.) with chimeric antibodies 
as indicated in each experiment. In some experiments 50 µg agonistic anti-CD40 
monoclonal antibody (MSKCC, Rockefeller Monoclonal Antibody Core Facility), or 30 
µg LPS (E.coli Serotype 0111:B4, Sigma) were co-injected with chimeric antibodies. To 
induce B cell germinal centers, mice were immunized with 100 µg KLH (Sigma) in alum 
(Thermo Scientific) 9 days before analysis. 
 
Adoptive transfer and T cell proliferation responses  
CD8+ and CD4+ OVA-specific T cells were isolated from OTI and OTII mice 
respectively. CD8+ Plasmodium yoelii CS-specific T cells were isolated from mice with 
transgenic TCR specific for H2Kd-SYVPSAEQI. CD8+ and CD4+ T cells were enriched 
with a CD8+ T cell isolation kit or a CD4+ T cells isolation kit, according to the 
manufacturer’s instructions (Miltenyi) with the addition of anti-CD11c-biotin to the 
antibody cocktail.  Enriched T cells were labeled with 3 µM 5-(6)-carboxyfluorescein 
diacetate succinimidyl diester (CFSE, Molecular Probes) in PBS 0.1% BSA for 10 min at 
37°C. The reaction was quenched with FCS and cells were washed 2-3 times. Enriched T 
cells (1 to 4 x 106) were injected intravenously into recipient mice. 24 hours later antigen 
was injected intraperitoneally. In experiments addressing antigen persistence, chimeric 
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antibodies containing antigen were injected 10, 7, 5, 3 or 1 day before T cell transfer. 
Proliferation of transferred T cells was analyzed after 3 days.  
 
Production of retroviruses 
DCIR2 was cloned into pMX-PIE vector carrying an IRES-GFP and puromycin 
resistance gene. DEC-205 was cloned into a modified pMX-PIE vector containing 
puromycin resistance gene, but no IRES-GFP. Deletions on the cytoplasmic tail of DEC-
205 were introduced by overlapping PCR and alanine substitutions were introduced by 
site-directed mutagenesis PCR. All plasmids were verified by sequencing. BOSC 23 cells 
were cotransfected with pMX-PIE vector and pCL-ECO plasmids and supernatants 
containing virus were harvested after 48 and 72 hours. Cells were spin-infected with 
retrovirus containing filtered supernatants mixed with 10 µg/ml polybrene (Sigma) and 
20 mM HEPES.  
 
Antigen presentation assay with transduced GM-DCs 
Bone marrow cells were obtained by flushing femurs and tibiae with RPMI supplemented 
with 5% FCS. Red blood cells were removed by ACK lysis (Gibco) and washed with 
complete RPMI. 
 
For GM-DCs differentiation (Inaba et al., 1992a), bone marrow cells were plated at 1.5 
x106/ml in complete RPMI with 3% vol/vol supernatant of J558L cells transduced with 
murine GM-CSF (provided by A. Lanzavecchia). Cells were cultured at 37°C and 5% 
CO2. Media was changed every 2 days, removing loosely adherent and dead cells. GM-
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DCs were infected with retrovirus containing supernatants on day 2, 3 and 4. On day 6 
transduced GM-DCs were assayed for expression of DCIR2, DEC-205 and GFP, and 
CD11c+GFP+ and CD11c+GFP- cells were purified by cell sorting. Purified cells were 
incubated for 16 hours with 1 µg/ml anti-DCIR2-OVA, anti-DEC-OVA or Iso-OVA, and 
100 ng/ml LPS for further 12 hours. Cells were then washed and co-cultured with OT-II 
T cells, and T cell proliferation was determined by [3H]-thymidine incorporation 48 hours 
later. 
 
Antigen presentation and internalization assays with transduced B cells 
Naïve B cells were isolated from DEC-205 deficient mice. Single cell suspensions from 
spleen were incubated with anti-CD43 beads (Miltenyi) and enriched in LS columns to 
obtain CD43- naïve B cells. Enriched B cells were plated at 0.7 x106 cells/ml in complete 
RPMI supplemented with 25 µg/ml LPS (Sigma) and 5 ng/ml IL-4 (Sigma) and cultured 
37°C and 5% CO2. B cells were infected with retrovirus-containing supernatants on day 1 
and 2. Transduced B cells were selected with puromycin from day 3 to 5, and live B cell 
blasts separated with Ficoll-Paque Plus (GE Healthcare) gradient.  
 
To measure cell associated OVA, 60,000 B cells were incubated with anti-DEC-OVA 
(10, 30, 100, 300, 1,000, 3000, 10,000 ng/ml) for 20 min on ice. Excess unbound 
antibody was removed by washing, and B cells were fixed and stained with rabbit anti-
OVA (Cappel) followed by anti-rabbit Cy5 (mouse, Jackson Immunoresearch). OVA 
content was quantified by flow cytometry based on mean fluorescence intensity. For 
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antigen presentation assessment 30,000 anti-DEC-OVA pulsed B cells were incubated 
with CFSE labeled OTI or OTII T cells for 3-4 days as described bellow. 
 
To measure DEC internalization, transduced B cells were incubated with anti-DEC-Alexa 
Fluor 647 (NLDC, rat monoclonal, in house labelling) on ice for 20 min. Excess antibody 
was removed, and cells were either kept on ice or incubated for 90 min at 37°C. 
Extracellular DEC-205 was detected with anti-rat PE (goat F(ab’)2, Santa Cruz). 
Internalization was calculated for DEC (Alexa Fluor 647)+ B cells according to the 
following formula: 100- [MFI anti-rat PE (90 min at 37°C) x 100] / MFI anti-rat PE (ice). 
 
Isolation and sorting strategy for DCs and activated monocytes 
Dendritic cells were isolated from mice that were injected with 1-2 106 B16-FL 
melanoma cells 9-12 days before euthanasia (Mach et al., 2000). All experiments were 
also performed, at least once, with dendritic cells isolated from naïve mice (no FL 
administration), with identical results. For in vivo targeting experiments, mice were 
injected intraperitoneally with 10 µg of fusion antibodies 8-12 hours before euthanasia.  
 
Activated DCs and monocytes were isolated from mice that were primed and boosted 
with methylated BSA (mBSA) in complete Freund’s adjuvant (CFA, Difco) and then 
injected intraperitoneally 24 hours before analysis with 100 µg mBSA (Sigma) as 
described (Cook et al., 2004; Naik et al., 2006). Tip-DCs were isolated from mice 
intravenously injected with 3,000 Listeria monocytogenes (gift from E. Pamer), 45 hours 
before euthanasia (Busch et al., 2001). L. monocytogenes was grown in brain hearth 
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infusion broth until early log-phase, monitored by light absorbance (A600) and ascertained 
by colony counting after plating into agar plates. 
 
Spleens were removed, injected with 0.4 U/ml collagenase D type II (Roche) in HBSS 
(Gibco) with 2% FCS and cut into small fragments, before 30 min digestion at 37°C. 
Digestion was stopped, with 5 mM EDTA (Gibco) for 5 min, before collection of cell 
suspensions.  Red blood cells were removed by ACK lysis (Gibco). All subsequent steps 
were performed in PBS 2% FCS and during incubations, cells were kept on ice. Non-
specific binding was blocked with purfied Fc block and DCs were enriched with anti-
CD11c beads (Miltenyi) according to manufacturer’s instructions. Enriched naïve 
CD11c+ cells were stained and sorted as follow: CD8+ DCs (B220-, NK1.1-, CD11chi, 
CD8+) and CD8- DCs (B220-, NK1.1-, CD11chi, CD8-, CD4+). Enriched CD11c+ cells 
from immunized mice were stained and sorted as follow: iMono (CD8-, CD11bhi, 
CD11cint and Ly6C+), iCD8- DCs (CD8-, Ly6C-, CD11bint and CD11chi) and iCD8+ DCs 
(CD8+, CD11chi and Ly6C-). In mice infected with L. monocytogenes, Tip-DCs were 
enriched with CD11c and CD11b beads and sorted as CD8-, CD11bhi, CD11clow/int and 
Ly6C+. Cells were also stained with B220, NK1.1, CD3, Ter119, Ly6G to gate out non-
DCs/non-monocytes. In addition, in experiments with CD11c-hDEC mice, cells were 
stained with humanCD205 to sort positive cells. Sorted populations were collected in 
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Culture and sorting strategy for DCs cultured from bone marrow progenitors 
GM-DCs were cultured as described above and collected at day 7. Non-specific binding 
was blocked with Fc block and cells were stained with CD11c. CD11chi cells were sorted.  
 
For FL-DC differentiation (Brasel et al., 2000), bone marrow cells were plated at 1.5 
x106/ml in complete RPMI with 100 ng/ml murine FL. FL was produced by anti-FLAG 
purification of supernatant from Chinese hamster ovary (CHO) cells expressing 
recombinant murine FL-FLAG (kindly provided by C.G. Park, The Rockefeller University). 
Cells were cultured at 37°C and 5% CO2 for 10 days. FL-DCs were collected, non-
specific binding was blocked with purified Fc block and cells were stained and sorted as 
follow: FL-CD8-DCs (B220-, CD11chi, SIRPαhi and CD24lo) and FL-CD8+DCs (B220-, 
CD11chi, SIRPαlo and CD24hi) (Naik et al., 2005).  
 
In vitro activation of DCs was by addition of 1µg/ml LPS (Sigma) for the last 18 hours of 
culture. In experiments with CD11c-hDEC mice, cells were also stained with 
humanCD205 to sort positive cells. Sorted populations were collected in RPMI 10% FCS 
and live cells were typically >95% pure. 
 
B cell culture  
Naïve B cells were isolated from WT C57BL/6 or B1-8hi mice, as indicated. For WT 
single cell suspensions from spleen were incubated with anti-CD43 beads (Miltenyi) and 
enriched in LS columns to obtain CD43- naïve B cells. For B1-8hi mice, single cell 
suspensions from spleen and skin-draining lymph nodes were incubated with anti-Igκ-PE 
(187.1, BD) followed by anti-PE beads (Miltenyi) and anti-CD43 beads (Schwickert et 
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al., 2007). Cells were enriched in LS columns (Miltenyi) to obtain CD43-Igκ- naïve λ+ B 
cells (NP-specific). Enriched B cells were plated at 0.7 x106 cells/ml in complete RPMI 
supplemented with 25 µg/ml LPS (Sigma) and 5 ng/ml IL-4 (Sigma) and cultured 37°C 
and 5% CO2 for 2-5 days. Alternatively, where indicated, B cells were cultured with 5 
µg/ml anti-CD40 (IC10 clone, purified from hybridoma). 
 
In vitro antigen delivery 
Sorted APCs were counted, and 15,000 live cells cells/well were plated in complete 
RPMI in 96-well round bottom plates. For B cell blasts, 30,000 cells/well were plated.  
Antigen was added at the indicated concentrations. For receptor-mediated endocytosis 
(DEC-205 targeting and BCR targeting), all media was kept ice cold and antigen was 
pulsed for 20 min on ice. For pinocytosis, warm media with antigen (OVA-biotin) was 
added and plates were incubated at 37°C with 5% CO2 for 2 hours. As controls in all 
experiments, APCs were also incubated with peptides for 20 min on ice: 
EQLESIINFEKLTEW peptide for OTI co-culture, and LSQAVHAAHAEINEAGR 
peptide for OTII co-culture, synthesized by the Proteomics Resource Center, The 
Rockefeller University. Cells were washed 3 times with complete RPMI to remove 
excess antigen or peptide. All incubations were done in duplicate wells. 
 
In vitro phagocytosis 
Enriched cells from spleen of naïve, immunized or Listeria infected mice, or GM-DCs 
were incubated with OVA-adsorbed fluorescent red beads in complete RPMI for 30 min 
at 37°C and 5% CO2. Cells were washed 3 times with cold PBS (900 rcf, 5 min), and 
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stained as described above. Specific populations containing no beads, 1 OVA-bead or 
more than 2 OVA-beads were sorted and co-cultured with CFSE labeled OVA-specific T 
cells. 
 
In vitro antigen presentation assay 
CD8+ and CD4+ OVA-specific T cells were isolated from OTI and OTII mice 
respectively, and labeled with 1 µM CFSE, as described above.  
 
100,000 to 125,000 T cells were added to each well containing APCs in “U” bottom, 96-
well plates. Activation and division of OVA-specific T cells was determined by flow 
cytometry after culture at 37°C and 5% CO2 for 60-65 hours (OTI cells) or 80-85 hours 
(OTII cells). For analysis, cells were stained with Vα2 PE, CD69 APC, CD8 or CD4 
PerCP and 0.5 µg/ml DAPI before acquisition in a LSR II (BD). 
 
Quantification of antigen capture 
 APCs were resuspended in Cytofix/Cytoperm (BD) for 15 min at room temperature and 
washed in Perm/Wash (BD). Anti-DEC-OVA and NP-OVA captured by receptor-
mediated endocytosis were detected with rabbit polyclonal anti-OVA (Cappel) followed 
by anti-Rabbit-HRP (donkey F(ab’)2, Jackson Immunoresearch) in PBS 1% BSA 0.1% 
saponin. OVA-biotin was detected with streptavidin-HRP (Jackson Immunoresearch). 
HRP content was assessed by a fluorometric assay with amplex red (Invitrogen). Plates 
were excited at 530 nm and emission was collected at 590 nm on Cytofluor II (Perseptive 
Biosystems). 
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Image Stream 100 analysis 
CD8+ and CD8- DCs from naïve mice, or activated monocytes (iMono) from immunized 
mice, or GM-DCs that had captured a single OVA-bead were sorted as described. After 
sorting, cells were stained on ice in PBS 1% BSA 0.05% azide with CD11c-, CD11b-, 
CD8- and MHCII-biotin, followed by streptavidin Pacific blue and analyzed on Image 
Stream 100 (Amnis). In focus, single cells were gated, and the Pacific blue membrane 
staining was used to create a mask to enable analysis of internalization according to 
manufacturer’s instructions (Amnis). Histograms were generated showing the distribution 
of internalization scores where positive scores indicate internalization.  
 
Data analysis  
Graphs were compiled on Prism software (GraphPad Software, Inc). Antigen pulse 
curves representing antigen uptake or T cell proliferation were adjusted to exponential 
one-phase association curves. 
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Chapter 3 
 
Results Part I 
 
Dendritic cells orchestrate T-cell responses, yet the role of DC subsets in establishing 
different types of T cell immunity is just beginning to be understood. In murine spleen, 
two major types of DCs can be identified: CD8+DEC-205+ DCs and CD8-DCIR2+ DCs 
(Fig. 1A). These DC subsets reside in different anatomic locations: CD8+DEC-205+ DCs 
are prevalent in the T-cell zone, whereas CD8-DCIR2+ DCs are in the red pulp and 
marginal zone (Fig. 1B). 
 
When isolated and cultured, DCs can undergo maturation, thus the role of different DC 
subsets would be best studied in vivo. This was facilitated by techniques to target DCs in 
vivo, using chimeric anti-DEC antibodies to deliver antigens to CD8+ DCs (Hawiger et 
al., 2001). Diana Dudziak identified the DCIR2 lectin as the antigen for the 33D1 
antibody, prompting the cloning of the 33D1 antibody to produce chimeric antibodies for 
antigen delivery to CD8-DCIR2+ DCs (Dudziak et al., 2007). When anti-DCIR2-OVA 
antibodies were injected into mice, specific antigen delivery to CD8- DCs was achieved 
(Fig. 1C). Anti-DEC-OVA antibodies ensured delivery to CD8+ DCs, and Iso-OVA 
antibodies did not deliver antigens to DCs (Fig. 1C). Both anti-DEC and anti-DCIR2 
antibodies were internalized (Dudziak et al., 2007), albeit with different efficiencies (to 
be discussed later). 








Figure 1. Expression profile and in vivo antigen targeting to DEC-205 and DCIR2 A, 
Dot plots show expression of DEC-205 and CD8α (left) and DCIR2 and CD8α (right) on 
CD11chi splenocytes analyzed by flow cytometry. B, panels show immunofluorescence 
on spleen sections for DEC-205 (left), DCIR2 (center) and Isotype control (left) in green, 
and CD3 in red (T-cell zone) and IgD in blue (B-cell follicles). C, Histograms show 
extracellular detection of anti-DCIR2 and anti-DEC antibodies on CD8- and CD8+ DCs 
30 min after intravenous injection of 10 µg of anti-DCIR2-OVA, anti-DEC-OVA, or 
control Iso-OVA antibodies, visualized with anti-mouse IgG1-FITC. Data is 
representative of at least 2 independent experiments. 
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Antigen targeting to CD8- DCs enabled the direct comparison of antigen processing and 
presentation capacity by the two major DC subsets: CD8+DEC-205+ and CD8-DCIR2+.  
To assess antigen presentation in vivo, OVA specific CD8+ OTI and CD4+ OTII T cells 
were labeled with 5-(6)-carboxyfluorescein diacetate succinimidyl diester (CFSE), a 
reporter dye for cell division, transferred to a new host and monitored after antigen 
administration. Both anti-DCIR2-OVA and anti-DEC-OVA elicited MHCII and MHCI- 
restricted T cell responses with only 300 ng of chimeric antibody administration (Fig 2A, 
by Diana Dudziak). In vivo dose responses analysis showed that anti-DCIR2-OVA was 
10 fold less efficient at MHCI presentation (OTI T cell proliferation) than anti-DEC-
OVA. Conversely, for MHCII presentation (OTII T cell proliferation), anti-DCIR2-OVA 
was 10 fold more effective than anti-DEC-OVA (Fig. 2A, by Diana Dudziak).  Antigen 
presentation after a single dose of chimeric antibody was long lasting; anti-DEC-OVA 
elicited OTI proliferation when T cell transfer occurred up to 10 days after antigen 
administration and anti-DCIR2-OVA elicited OTII proliferation when T cells were 
transferred up to 5 days after antigen administration (Fig. 2B).  
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The superiority of DEC-205 targeting to CD8+ DCs in eliciting MHCI-restricted 
responses was also observed in BALB/c mice. Chimeric anti-DEC antibodies carrying a 
CD8+ T cell epitope from the circumsporozoite protein (CS) of Plasmodium yoelii (anti-
DEC-CSpep) were at least 10 fold better than anti-DCIR2-CSpep at triggering T cell 
division of transferred CS-specific CD8+ T cells (Fig. 2C). These results combined show 
that antigen delivery with anti-DCIR2 to CD8- DCs elicits better activation of CD4+ T 
cells, while antigen delivery with anti-DEC to CD8+ DCs results in more efficient 
activation of CD8+ T cells. 
  
Antibodies that recognize peptide-MHC complexes can be used to directly measure 
antigen presentation. For MHCI presentation, the 25D1 antibody was described to 
recognize the OVA peptide SIINFEKL in H-2Kb molecules (Porgador et al., 1997). 
Despite several attempts using the 25D1 antibody no significant signal in DCs after anti-
DEC-OVA administration was detected, neither in vivo nor in vitro. For monitoring 
peptide-MHCII complexes, there is an antibody that detects the Y-Ae peptide displayed 
by IAb molecules (Murphy et al., 1989). However no chimeric antibodies (anti-DCIR2 or 
anti-DEC) carrying the Y-Ae peptide could be produced; the antibodies where unstable, 
and purified antibodies were devoid of the Y-Ae peptide. I was finally successful when 
producing chimeric antibodies carrying a HEL peptide (Hawiger et al., 2001) and 
assessing IAk-HEL peptide formation using the Aw3.18 antibody (Dadaglio et al., 1997) 
in B10.BR mice. 








Figure 2. CD4 and CD8 T cell responses to antigens targeted in vivo to different DC 
subsets. A, Histograms show proliferation as measured by CFSE dye dilution of 
transferred OTI (left) or OTII (right) T cells, after injection of varying amounts of anti-
DCIR2-OVA, anti-DEC-OVA or control Iso-OVA antibodies. B, as in A, but T cells 
were transferred 1, 3, 5, 10 or 20 days after injection of 3 µg of DCIR2-OVA, anti-DEC-
OVA or Iso-OVA. C, Histograms show proliferation of transferred CS-specific CD8+ T 
cells after injection of varying amounts of anti-DCIR2-CSpep, anti-DEC-CSpep or 
control Iso-CSpep antibodies into BALB/c mice. Data is representative of at least 2 
independent experiments. 
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Figure 2
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CD8+ DCs showed small amounts of surface MHCII-HEL at 3 hours after injection of 
anti-DEC-HEL, but after 24 hours it was below detection (Fig. 3A). In contrast, CD8- 
DCs targeted with anti-DCIR2-HEL displayed high levels of MHCII-HEL after 3 hours, 
and it remained high for 2 days (Fig. 3A). Antigen presentation was independent of DC 
activation, since neither DEC or DCIR2 targeting induced changes in expression of 
CD40, CD69, CD80, CD86 or MHCII (Dudziak et al., 2007). Moreover, all chimeric 
antibodies produced had no detectable levels of LPS and similar results were obtained in 
LPS-insensitive C3H/HeJ mice, which have a spontaneous mutation in TLR4 (Fig. 3B).  
 
Targeting antigens to DCs with anti-DEC or anti-DCIR2 chimeric antibodies in the 
steady state leads to tolerogenic antigen presentation, whereas concomitant 
administration of DC maturation stimuli (such as anti-CD40 and polyinosinic 
:polycytidylic acid) promotes T cell activation and immunity (Bonifaz et al., 2002; 
Bonifaz et al., 2004; Boscardin et al., 2006; Dudziak et al., 2007; Hawiger et al., 2001; 
Hawiger et al., 2004; Soares et al., 2007; Trumpfheller et al., 2006). Concomitant 
administration of LPS or anti-CD40 with anti-DCIR2-HEL resulted in similar MHCII-
HEL display on CD8- DCs as antigen administration without DC activation (Fig. 4A). 
Interestingly, concomitant administration of LPS with anti-DEC-HEL promoted a slight 
increased MHCII-HEL display (Fig. 4A). LPS administration increased DEC-205 
expression in DCs (not shown here) and had a more significant impact than anti-CD40 to 
induce DC maturation (Fig. 4B and C). 









Figure 3. MHCII-peptide complex formation on DCs after antigen targeting in vivo 
with anti-DCIR2 or anti-DEC-205 antibodies.  A, Histograms show MHCII-HEL 
peptide complexes on CD8+DEC205+ and CD8-DCIR2+ DCs, 30 min, 3 hours, and 1 or 2 
days after intravenous injection of 10 µg anti-DCIR2-HEL, anti-DEC-HEL or control 
Iso-HEL antibodies in B10.BR mice. B, as in A, but in C3H/HeJ, LPS-insensitive, mice. 
Data is representative of at least 2 independent experiments. 
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Figure 3









Figure 4. MHCII-peptide complex formation and DC activation after antigen 
targeting in vivo with maturation stimuli. A, Histograms show MHCII-HEL peptide 
complexes on CD8+DEC205+ and CD8-DCIR2+ DCs, 6 hours after intravenous injection 
of 10 µg anti-DCIR2-HEL, anti-DEC-HEL or control Iso-HEL. Where indicated, LPS 
and anti-CD40 where co-injected with chimeric antibodies. B, as in A, but histograms 
show MHCII expression. C, as in A but histograms show CD86 expression. Data is 
representative of at least 2 independent experiments. 
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In conclusion, antigens delivered by anti-DCIR2 antibodies to CD8- DCs are processed 
and transferred to the cell surface as MHCII-peptide complexes more efficiently than 
antigens delivered by anti-DEC to CD8+ DCs, independent of  DC activation status. To 
determine whether the differences in antigen processing between the two DC subsets 
were due to the receptor targeted or to cell-intrinsic differences, transgenic mice 
expressing the human DEC-205 receptor (hDEC) on both DC subsets (CD11c-hDEC 
mice) were produced (C. Cheong, H-W. Lee and C.G. Park). CD11c-hDEC mice show 
position-effect variegation, but hDEC is equally expressed and variegated in both CD8+ 
and CD8- DCs (Fig. 5A). Anti-hDEC-HEL antibodies, that do not cross-react with 
endogenous mouse DEC-205 molecules, were cloned (C. Trumpfheller) and produced to  
target both DC subsets in hDECxB10.BR mice. CD8- DCs showed significantly higher 
levels of MHCII-HEL than CD8+ DCs after anti-hDEC-HEL administration (Fig. 5B). 
Thus cell intrinsic differences determine the superiority of CD8- DCs over CD8+ DCs for 
MHCII presentation. 
 
For unknown reasons, no transgenic mice expressing DCIR2 under the control of the 
CD11c promoter could be obtained to perform reciprocal experiments. Thus, to further 
compare antigen presentation by anti-DEC and anti-DCIR2 antigen targeting in the same 
cell, GM-DCs were infected with retroviruses encoding DCIR2 and green fluorescent 
protein (GFP) (Fig. 6A). Transduced cells expressing DCIR2 were sorted based on GFP 
expression, then targeted with anti-DEC-OVA or with anti-DCIR2-OVA. LPS was added 
to induce GM-DC maturation, and MHCII presentation was analyzed by measuring the 
proliferation of co-cultured OTII T cells. MHCII presentation was equivalent, whether 
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OVA was captured by DEC-205 or DCIR2 (Fig. 6B). Thus, differential MHCII 
processing by DC subsets is an intrinsic property of the cells. 
 
In summary, I compared anti-DCIR2-OVA to anti-DEC-OVA targeting and observed 
that DCIR2 targeting was more effective for MHCII presentation whereas DEC-205 
targeting was more efficient for cross-presentation into MHCI. In addition, I was able to 
demonstrate that CD8- DCs are better for MHCII antigen processing, independent of the 
receptor used for antigen capture.  








Figure 5. hDEC-205 expression and MHCII-peptide complex formation on DCs 
after antigen targeting in vivo with anti-hDEC-HEL. A, Dot plots show CD8α and 
hDEC-205 expression on CD11chi splenocytes on CD11c-hDEC transgenic (left) and 
B10.BR (right) mice. B, Histograms show MHCII-HEL peptide complexes on 
CD8+DEC205+ and CD8-DCIR2+ DCs 30 min, 3 hours, and 1 day after intravenous 
injection of 30 µg of anti-hDEC-HEL into CD11c-hDEC transgenic (hDEC+) or control 
littermate (hDEC-) mice. Data is representative of at least 2 independent experiments. 





































Figure 6. Antigen targeting to GM-DCs. A, Histograms show DCIR2 and isotype rat 
IgG2b (left) and DEC-205 and isotype rat IgG2a (right) staining on day 6 DCIR2-GFP 
transduced GM-DCs, gated on CD11c+GFP+ (GFP pos) and CD11c+GFP- (GFP neg). B, 
Transduced GM-DCs were sorted into CD11c+GFP+ and CD11c+GFP- and incubated 
with 1 µg /ml anti-DCIR2-OVA, anti-DEC-OVA or Iso-OVA and then LPS. Cells were 
washed and co-cultured with OTII T cells. Graph shows T cell proliferation measured by 
[3H]-thymidine incorporation. Data is representative of 2 independent experiments. 
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I next sought to understand if the differences between CD8+ and CD8- DCs for MHCI 
cross-presentation were also due to cell-intrinsic differences. CD11c-hDEC mice were 
injected with anti-DCIR2-OVA, anti-mouse-DEC-OVA (anti-mDEC-OVA) and anti-
hDEC-OVA. hDEC-expressing CD8+ and CD8- DCs were purified by cell sorting and 
evaluated for MHCI presentation by co-culture with CFSE labeled OTI T cells. To 
confirm the previous results on MHCII presentation, sorted DCs were also co-cultured 
with CFSE labeled OTII T cells. As previously documented, CD8- DCs targeted in vivo 
with anti-DCIR2-OVA efficiently induced OTII but not OTI proliferation; whereas CD8+ 
DCs targeted in vivo with anti-mDEC-OVA induced robust OTI but modest OTII 
proliferation (Fig. 7). Furthermore, when both DC subsets were targeted with anti-hDEC-
OVA, CD8- DCs were more effective at stimulating OTII proliferation than CD8+ DCs 
from the same mice (Fig. 7). In contrast, both CD8- and CD8+ DCs targeted in vivo with 
anti−hDEC-OVA elicited similarly robust levels of OTI proliferation (Fig. 7). These 
results indicate that both DC subsets have the same intrinsic potential to cross-present 
antigens when the antigen is delivered by DEC-205. 








Figure 7. hDEC-205-mediated endocytosis in vivo promotes cross-presentation by 
both CD8- and CD8+ DC subsets. A, Representative histograms show proliferation as 
measured by CFSE dye dilution of OTI (left) and OTII (right) T cells upon culture with 
5x103 CD8- or CD8+ DCs isolated from CD11c-hDEC transgenic mice injected with anti-
hDEC-OVA, anti-mDEC-OVA or anti-DCIR2-OVA, as indicated. B, Summary of 3 
independent experiments as in A, where panels show the percentage of divided, CFSE 
low OTI (left) and OTII (right) cells. Each symbol indicates independent experiments and 
represents the average of duplicate measurements. 
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Chapter 4 
 
Results Part II 
 
Internalization of anti-DCIR2 antibodies was slower than anti-DEC antibodies (Dudziak 
et al., 2007). I confirmed those results with in vitro pulse-chase experiments (Fig. 8). 
Splenocytes were incubated with anti-DCIR2 or anti-DEC antibodies on ice, excess 
antibodies were washed, and cells were incubated at 37°C for 20 to 240 minutes (Fig. 8A 
and B). Internalization of targeting antibodies was monitored by extracellular anti-Rat 
antibody detection. In addition, cells were fixed and permeabilized to detect total cell-
associated anti-DCIR2 or anti-DEC antibodies. For anti-DEC antibodies efficient 
internalization was confirmed as extracellular anti-Rat detection decreased over time at 
37°C (Fig. 8A upper panels and 8B). The total amount of anti-DEC antibodies associated 
with CD8+ DCs did not decrease over time (Fig. 8A upper panels and 8B). Conversely, 
the total amount of anti-DCIR2 antibodies associated with CD8- DCs correlated to the 
antibodies that remained in the plasma membrane, and total cell associated antibody 
sharply decreased over time (Fig. 8A lower panels and 8B). 
 
Similar results were obtained by Western blot detection of targeted anti-DEC and anti-
DCIR2 antibodies carrying the circumsporozoite protein from Plasmodium falciparum 
(CSf). Enriched CD11c+ splenocytes were incubated on ice with anti-DCIR2-CSf or anti-
DEC-CSf antibodies (kindly provided by S. Boscardin), and incubated for 10 to 180 
minutes at 37°C. Incubation with pH 3.6 buffer solution was used to remove antibodies







Figure 8. Internalization of anti-DEC-205 and anti-DCIR2. A and B, Splenocytes 
were incubated on ice, with either anti-DEC or anti-DCIR2 targeting antibodies, washed 
and incubated at 37°C for various lengths of time. Control cells were not incubated with 
targeting antibodies A, Histograms show detection of the targeting antibodies on the cell 
surface of the respective DCs (extracellular staining, left panels) or after fixation and 
permeabilization (total staining, right panels). B, Graph is a summary of A, where mean 
fluorescence values at time 0 were normalized to 100%. C. CD11c+ enriched splenocytes 
were incubated with anti-DEC-CSf or anti-DCIR2-CSf on ice, washed and incubated at 
37°C for various times. Indicated cell samples were treated with pH 3.6 buffer to remove 
extracellular antibodies. Protein extracts from cell samples were obtained and probed for 
CSf and β-actin by Western blot. Data is representative of at least 2 independent 
experiments. 
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from the plasma membrane and allow visualization of internalized antibodies. Anti-DEC 
not only delivered more antigen to DCs than anti-DCIR2, but also that internalization was 
faster and more effective (Fig. 8C). Even though acid stripping was not efficient at 
removing all anti-DEC-CSf antibodies from the cell surface, accumulation of internalized 
antibodies could be detected after 10 min. But internalized anti-DCIR2 antibodies could 
only be detected after 30 minutes (Fig 8C).  
 
To analyze the fate of anti-DEC and anti-DCIR2 antibodies after internalization in vivo, 
mice were injected with anti-DCIR2-HEL, anti-mDEC-HEL and control isotype-HEL 
and internalized antibodies were detected on permeabilized splenocytes. 30 minutes after 
administration both anti-DCIR2-HEL and anti-DEC-HEL could be detected inside CD8- 
and CD8+ DCs, respectively (Fig 9A). However, anti-DCIR-HEL antibodies could not be 
detected after 3 hours, while internalized anti-DEC-HEL antibodies could still be 
detected up to two days after administration (Fig 9A). 
 
To determine if the difference in the persistence of internalized antibodies was due to the 
receptor targeted (DEC or DCIR2) or cell intrinsic differences between DC subsets, 
similar experiments were performed in CD11c-hDEC transgenic mice. Anti-hDEC-HEL 
antibodies were detected in equivalent amounts inside both CD8- and CD8+ DCs (Fig. 
9B). In conclusion, anti-DEC antibodies are rapidly internalized and can be detected 
inside DCs for prolonged periods (at least 2 days). On the other hand, anti-DCIR2 
antibodies are internalized more slowly, and their detection inside DCs is less robust and 
only possible at early time-points (30 min). Those features are related to the receptor  








Figure 9. Persistence of internalized anti-DEC-205 antibodies in vivo. A, Histograms 
show internalized targeted antibodies on CD8+DEC205+ and CD8-DCIR2+ DCs, 30 min, 
3 hours, and 1 or 2 days after intravenous injection of 10 µg anti-DCIR2-HEL, anti-DEC-
HEL or control Iso-HEL antibodies into B10.BR mice. Internalized antibodies were 
detected by blocking extracellular antibodies with unlabeled anti-mouse IgG1, then 
splenocytes were fixed and permeabilized and intracellular targeting antibodies were 
detected with anti-mouse IgG1 FITC. B, as in A, but histograms show internalized 
targeted antibodies on CD8+DEC205+ and CD8-DCIR2+ DCs after intravenous injection 
of 30 µg of anti-hDEC-HEL into CD11c-hDEC transgenic mice or negative littermates 
(control). Data is representative of at least 2 independent experiments. 
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used for internalization. Supporting these conclusions, similar results were also obtained 
in a DC cell line transduced with DEC and DCIR2 (data not shown). 
 
When antigen was delivered by DEC-mediated endocytosis, both CD8+ and CD8- DCs 
were equivalent in cross-presentation. However, distinct internalization kinetics between 
DEC and DCIR2 impose certain difficulty in comparing differences in the intracellular 
route of the targeted antibodies. Thus to investigate whether the DEC-205 molecule 
direct antigens to a special intracellular route favoring cross-presentation, I started 
searching for alternative models. 
 
Even though DEC-205 is highly expressed by some subsets of DCs, it is not restricted to 
DCs; thymic epithelium and B cells, for example, also express DEC-205. However DEC-
205 expression in splenic B cells was evaluated to be at least one order of magnitude 
lower than in DCs, and it did not increase upon B cell culture with LPS, anti-CD40 or the 
combination of anti-IgM and IL-4 (Inaba et al., 1995). I repeated this analysis and found 
that germinal center B cells (Fas+, GL-7+) express DEC-205 at levels comparable to DCs 
(Fig. 10A). Germinal center B cells constitute a negligible population in naïve mice and 
therefore can be easily overlooked.  I also analyzed in vitro stimulation conditions that 
would promote DEC-205 expression in B cells. The combination of LPS and IL-4 or anti-
CD40 and IL-4 prompted high levels of DEC-205 expression in cultured B cells (Fig. 
10B and C). Interestingly, there was no direct correlation between the level of DEC-205 
expression and activation markers such as MHCII or CD86 (Fig. 10C). 









Figure 10. DEC-205 expression in B cells. A, Histograms show DEC-205 expression on 
germinal center B cells (CD19+ Fas+ GL-7+), CD8+ and CD8- DCs from WT or DEC-
205/- mice. B, Dot-plots show CD19 and DEC-205 or isotype staining on B cells cultured 
with LPS and IL-4 for 3 days. C, Graphs show expression of DEC-205, MHCII and 
CD86 on B cells cultured with different stimuli for 1, 2 or 3 days, as indicated. Data is 
representative of at least 2 independent experiments. 
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B cells are also professional antigen presenting cells and they rely on their B-cell receptor 
(BCR) for antigen capture. The BCR consists of a membrane-associated immunoglobulin 
(Ig), associated with invariant Igα-Igβ heterodimers. Cross-linking of the BCR triggers 
its internalization into antigen processing compartments and also initiates a signaling 
cascade that leads to B cell activation, enabling efficient antigen presentation. To 
compare DEC-mediated to BCR-mediated antigen capture for antigen presentation, B 
cells were isolated from B1-8hi mice, specific for NP (4-hydroxy-3-nitrophenil). B cells 
were cultured for 2 days in LPS and IL-4 and then pulsed with different concentration of 
either anti-DEC-OVA or OVA-NP. Excess antigen was washed off, and B cells were co-
cultured with CFSE labeled OVA-specific OTI or OTII T cells.  When the relative 
amount of antigen uptake is taken into account, similar results were obtained for MHCII 
presentation for antigens targeted to the BCR instead of DEC-205 (Fig. 11). However, 
antigen captured by DEC-205 was approximately three times more efficient than the 
BCR for cross-presentation (Fig. 11). This difference is not dependent on BCR cross-
linking, since anti-DEC-OVA together with BSA-NP was equivalent to anti-DEC-OVA 
alone, and OVA-NP3 was similar to OVA-NP30. 
 
The cytoplasmic tails of receptors contain amino acid motifs that are responsible for 
interacting with different adaptors and determine their intracellular sorting (Bonifacino, 
2003). Based on antigen presentation results, the intracellular sorting of DEC-205 might 
be important for delivering antigens to compartments that enhance cross-presentation. 
Hence, undertaking a genetic approach, the cross-presentation ability of different DEC-
mutants (Table 1) where the cytoplasmic portion was modified were compared. Different  








Figure 11. DEC-205-mediated endocytosis promotes cross-presentation in B cells. 
NP-specific B cells were isolated from B1-8hi transgenic mice and stimulated with LPS 
and IL-4 for 50-60 hours. A, The Y-axis shows relative cell-associated OVA, after 
targeting with the indicated concentrations of  anti-DEC-OVA, or anti-DEC-OVA and 
BSA-NP, or OVA-NP3, or OVA-NP30 on the X-axis. Maximum cell-associated OVA 
was normalized to 100 in each experiment. B, Activation and proliferation of OTI T cells 
(upper panel) and OTII T cells (lower panel) in response to OVA containing B cells. The 
Y-axis shows percentage of divided T cells. A and B represent pooled data from 3 
independent experiments. 
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DEC-205 mutants with deletions in the C-terminal cytoplasmic tail were designed. For 
example:  DEC-medium lacking the acidic cluster “EDE” that had been implicated with 
lysossomal targeting (Mahnke et al., 2000); and DEC-short lacking the “EDE” motif and 
the “FSSVRY” motif (implicated in coated pit localization) (Chen et al., 1990; Collawn 
et al., 1990; Paccaud et al., 1993). In addition, mutant DEC-205 molecules containing 
substitutions of three consecutive amino acids to alanines were also designed. 
 
Table 1: Amino acid sequence of the cytoplasmic tail of wild type DEC-205 and of 
engineered DEC-mutants 
Receptor cytoplasmic tail 
DEC_WT T M Q R S H I R W T G F S S V R Y E H GT N E DE VM LP SF HD - C  
DEC_medEDEVMLP T M Q R S H I R W T G F S S V R Y E H GT N E DE VM LP - C  
DEC_med+EDE T M Q R S H I R W T G F S S V R Y E H GT N E DE - C  
DEC_medium T M Q R S H I R W T G F S S V R Y E H G - C  
DEC_short T M Q R S H I R W T G - C  
DEC_VRYtoAAA T M Q R S H I R W T G F S S A AA EH GT N E DE VM LP SF HD - C  
DEC_EDEtoAAA T M Q R S H I R W T G F S S V R Y E H GT N A AA VM LP SF HD - C  
DEC_VMLtoAAA T M Q R S H I R W T G F S S V R Y E H GT N E DE AA A P SF HD - C  
  TM: Transmembrane     C: C-terminus     FSSVRY     EDE 
 
Mouse DEC-205 molecules (WT and mutant versions) were cloned into retroviral vectors 
that contained a puromycin resistance gene. Ideally, I wanted to perform experiments 
using bona fide DCs; however after isolation, DCs do not divide or survive long, and 
heterologous protein expression is not optimal. Therefore DC cell lines were obtained 
and transduced. D1 cells (Winzler et al., 1997) were difficult to grow and maintain, and 
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no transduced cell lines could be selected. DC2.4 cells (Shen et al., 1997) could be 
transduced and selected, but the cells were unable to activate antigen specific CD4+ T 
cells (even with exogenous peptide loading and additional stimulation with cytokines and 
TLR ligands). Moreover, DC2.4 cells were not optimal to present exogenous antigens to 
CD8+ T cells. Hence, I decided to study the role of DEC cytoplasmic tail on transduced 
primary B cells stimulated with LPS and IL-4.  
 
B cells from DEC-205 deficient mice were transduced with DEC-WT and DEC-mutants. 
DEC mRNA is 5.2 kilobases, limiting efficient packaging into viruses. However, after 
puromycin selection, enriched transduced cells could be obtained. Transduced B cells had 
very different membrane expression levels of the DEC-mutants; therefore it was 
imperative to measure the amount of OVA bound by each receptor after anti-DEC-OVA 
targeting. Transduced B cells were pulsed on ice with different concentrations of anti-
DEC-OVA, washed and stained with rabbit anti-OVA antibodies to assess the amount of 
OVA captured. Replica plates of antigen pulsed B cells were co-cultured with CFSE 
labeled OTI or OTII T cells. To evaluate the efficiency of antigen presentation, corrected 
for the amount of antigen captured, the results are displayed in the same graph: the 
amount of captured OVA on the X-axis and T-cell proliferation on the Y-axis (Fig. 12A 
and C). In addition, DEC-205 endocytosis was measured to evaluate antigen 




                 71
Surprisingly, except for the DEC-short tail, which was severely impaired for 
internalization (Fig. 12B) and thus showed a reduction in cross-presentation and MHCII 
presentation (Fig. 12A), none of the DEC mutations assayed significantly impacted 
antigen processing and presentation for CD4+ or CD8+ T cells (Fig. 12). In conclusion, 
the amount of antigen captured and internalized seems to be the main factor that controls 
the level of MHCII presentation or cross-presentation. 






Figure 12. Most mutations in the cytoplasmic tail of DEC-205 do not disrupt 
internalization or antigen presentation. A, Naïve B cells from DEC-205-/- mice were 
stimulated with LPS and IL-4 and transduced with DEC-wt or DEC-mutants with 
deletions in the cytoplasmic tail, according to table 1. Enriched transduced cells were 
pulsed with anti-DEC-OVA (1-10,000 ng/ml).  Cell-associated OVA was assessed with 
rabbit anti-OVA (mean fluorescence intensity on the X-axis), and B cells were co-
cultured with OTI T cells (upper panel) or OTII T cells (lower panel). The Y-axis shows 
percentage of divided T cells in response to OVA containing B cells. B, as in A, but 
percentage of DEC-205 internalization is shown. B cells were stained on ice with anti-
DEC antibodies, followed by incubation at 37°C for 3 hours. Anti-DEC antibodies 
remaining on the cell surface were detected with anti-Rat staining and the percentage of 
internalization was calculated. C and D, as in A and B, but DEC-mutants had 
substitutions of 3 residues in the cytoplasmic tail for 3 alanines, as indicated. Data is 
representative of at least 2 independent experiments. 
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Chapter 5 
 
Results Part III 
 
A key factor that impacts antigen presentation of a given peptide is the amount of antigen 
captured. Yet very few studies on antigen presentation measure antigen uptake. In vivo, 
this caveat can be justified because antigen capture and presentation constitute a 
continuous process where after internalization the antigen is processed into peptides in 
order to be loaded onto MHC molecules and presented to T cells. Antigen processing into 
peptides hampers methods of antigen detection that rely on protein integrity.  
 
The route of antigen capture also impacts antigen presentation: recently it has been show 
that OVA uptake by the mannose receptor potentiates cross-presentation (Burgdorf et al., 
2007). In addition, when antigen is delivered by DEC-mediated endocytosis, both CD8+ 
and CD8- DCs are equivalent in cross-presentation (Fig. 7). And in B cells DEC-mediated 
antigen uptake is more efficient than the BCR for cross-presentation (Fig. 11).  
 
Finally cell intrinsic factors also modulate antigen presentation: CD8- DCs are better at 
MHCII presentation than CD8+ DCs, even when antigen is targeted to the same receptor 
(hDEC) (Fig. 5 and 6)(Dudziak et al., 2007). Although both subsets of DCs express 
similar levels of hDEC-205 in CD11c-hDEC transgenic mice (Dudziak et al., 2007), 
differences in antigen presentation may nevertheless be the result of differences in the 
amounts of antigen captured. To explore this possibility I isolated spleen CD8- and CD8+ 
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DCs from CD11c-hDEC mice, pulsed them on ice with varying amounts of anti-hDEC-
OVA and measured the amount of cell-associated OVA (Fig. 13A, left). Replica plates of 
pulsed DCs were co-cultured with CFSE labeled OTI or OTII transgenic T cells to 
measure their ability to present OVA (Fig. 13B, left). As a further control, DCs were 
pulsed with peptides to measure their antigen presenting activity independent of antigen 
capture and processing (Fig. 13C, left).  
 
CD8- and CD8+ splenic DCs captured similar amounts of OVA when pulsed with anti-
hDEC-OVA (Fig. 13A, left) and showed similar intrinsic antigen presenting activity 
when pulsed with peptides (Fig. 13C, left). When antigen was titrated under conditions 
where DCs were present in excess, the results of in vitro targeting mirrored those 
obtained in vivo in that the two subsets were equivalent for MHCI cross-presentation and 
also that CD8- DCs were intrinsically more efficient than CD8+ DCs in processing and 
presenting antigens in MHCII (Fig. 13B, left). Small differences in presentation were 
found when the number of antigen presenting cells were titrated: CD8+ DCs were about 3 
fold more effective than CD8- DCs for cross-presentation when less than 10,000 DCs 
were present (Fig. 14). In contrast, CD8- DCs were several orders of magnitude more 
efficient than CD8+ DCs for MHCII presentation, irrespective on the number of DCs 
assayed (Fig. 14). In conclusion, CD8- and CD8+ splenic DCs are similar in terms of their 











Figure 13. Antigen presentation after receptor-mediated endocytosis in vitro. A-C, 
APCs from CD11c-hDEC mice were isolated from naïve (solid lines) or mBSA-CFA 
immunized (dashed lines) mice (left panels), or cultured from bone marrow (right 
panels). A, The Y-axis shows relative cell-associated OVA, as measured by rabbit anti-
OVA and developed with anti-rabbit-HRP, after targeting with the indicated 
concentrations of anti-hDEC-OVA on the X-axis. B, Activation and proliferation of OTI 
T cells (upper panels) and OTII T cells (lower panels) in response to OVA containing 
APCs. The Y-axis shows the percentage of divided T cells. C, Graphs show OTI (upper 
panels) and OTII (lower panels) proliferation in response to peptide pulsed APCs. D-F, 
APCs were isolated from spleen or cultured from bone marrow of WT mice. Dashed lines 
indicate LPS activation. D and E, as in A and B, but targeting was with anti-mouse-DEC-
OVA. F, As in C. Graphs represent pooled data from 3-7 independent experiments.  
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Figure 13









Figure 14. Antigen presentation after receptor-mediated endocytosis in vitro: APC 
titration. APCs were isolated from spleen or cultured from bone marrow of naïve 
CD11c-hDEC mice. A, Activation and proliferation of OTI T cells (upper panel) and 
OTII T cells (lower panel) in response to APCs targeted with 300 ng/ml of anti-hDEC-
OVA. The Y-axis shows the percentage of divided T cells. The X-axis shows the number 
of APCs plated in each 96-well. B, Graphs show OTI (upper panel) and OTII (lower 
panel) proliferation in response to peptide pulsed APCs. Graphs represent pooled data 
from 2 independent experiments.  
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During some infections or inflammation, monocytes become activated, acquire some DC 
features and can differentiate into tip-DCs (Naik et al., 2006; Serbina et al., 2008; Serbina 
et al., 2003). At least in some situations, this process is GM-CSF dependent (Cook et al., 
2004) (Fig. 15). Conversely, conventional DCs are FL-dependent, GM-CSF-independent 
and derived from pre-DCs (Waskow et al., 2008). In order to compare activated 
monocytes to conventional DCs, hDEC-205 transgenic mice were immunized with 
antigen in complete Freund’s adjuvant (CFA) and then challenged with antigen to induce 
monocyte activation (Cook et al., 2004). Activated monocytes were CD11c+ but also 
Ly6C+, and had similar levels of CD86, 2- fold higher levels of MHCI but lower levels of 
MHCII when compared to conventional DCs from naïve mice (Fig. 15 and 16). Activated 
monocytes, unlike DCs, were positive for M-CSF receptor but negative for Flk2 (FL 
receptor), DEC-205 and DCIR2 (Fig. 15). Conventional DCs isolated from the 
immunized mice (iCD8+ and iCD8- DCs) had higher levels of CD86, MHCI and MHCII 
when compared to control DCs from naïve mice (Fig. 15 and 16).  
 
Activated monocytes and conventional DCs were purified by cell sorting, as described in 
methods, and compared for antigen presentation after targeting with anti-hDEC-OVA. 
All cell types isolated from immunized mice were similar to control DCs in antigen 
uptake after anti-hDEC-OVA targeting (Fig. 13A, left) (Platt et al., 2010). However, DCs 
from immunized mice were more efficient than their naïve counterparts with regards to 
the presentation of pulsed peptides. On the other hand, activated monocytes were less 
efficient than DCs, especially for MHCII presentation, when pulsed with peptides (Fig. 
13C, left). Consistent with the peptide presentation experiments, activated monocytes  






Figure 15. Activated monocytes differ from conventional DCs in that they are GM-
CSF dependent and do not express Flk2 but express M-CSF receptor. WT and 
GMCSF-Rβ KO (GMR KO) mice were immunized with mBSA-CFA and i.p. challenged 
with mBSA 24 hours before analysis. A, Representative flow cytometry profile of 
splenocytes (after exclusion of T cells, B cells, NK cells, granulocytes and pDCs) 
showing CD11c and CD11b expression (upper panels). Sorting strategy for activated 
monocytes (CD11c+) and CD8-DCs, after further gating on CD11b+ CD8- cells (lower 
panels). B, Absolute number of different cell populations in the spleen, where N stands 
for naïve mice and I for immunized mice. Graph shows mean ± SE, of two independent 
experiments with three mice/group each. C, Representative histograms show CD86, 
MHCI and MHCII expression on the different cell populations. D, Representative dot-
plots show expression of CD11b, CD11c, DCIR2, DEC-205, CD135 (Flk2) and CD115 
(M-CSF receptor) on monocytes, CD8+ DCs, CD8- DCs and activated monocytes 
(CD11c+, iMono). 
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Figure 15











Figure 16. CD86, MHCI and MHCII expression. CD86 (A), MHCI (B) and MHCII 
(C) expression on the indicated APCs. The mean fluorescence intensity is represented in 
the Y-axis. Data represents the mean± SE from 3 independent experiments. 
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performed poorly in MHCII presentation but showed levels of cross-presentation that 
approached those of conventional DCs (Fig. 13B, left). Thus, activated monocytes 
resemble conventional DCs in their ability to cross-present antigens captured by receptor-
mediated endocytosis. However, under the same conditions, activated monocytes are far 
inferior to naïve or activated conventional spleen DCs with regards to MHCII 
presentation. 
 
DCs can be obtained by culturing murine bone marrow cells with GM-CSF (GM-DCs) 
(Inaba et al., 1992a) or FL (FL-DCs)(Brasel et al., 2000). FL-DCs are heterogeneous and 
contain cells that resemble CD8+ and CD8- splenic DCs (FL-CD8+ and FL-CD8- DCs 
respectively) (Naik et al., 2005; Weigel et al., 2002). Both FL- and GM-DCs can be 
activated with TLR agonists, such as LPS, to increase the expression of MHC and co-
stimulatory molecules (Brasel et al., 2000; Cella et al., 1997; Pierre et al., 1997) as well 
as antigen processing (Inaba et al., 2000; Trombetta et al., 2003) and the stability of 
MHC-peptide complexes on the cell surface (Shin et al., 2006; Trombetta and Mellman, 
2005). Moreover, endogenous mouse DEC-205 expression is induced on cultured DCs 
upon TLR ligation (Brasel et al., 2000; Inaba et al., 1995) and also on B cells after culture 
with LPS and IL-4 (Fig. 10). 
 
In order to compare the ability of tissue culture-derived DCs and conventional DCs from 
spleen to present antigens captured by receptor-mediated endocytosis, GM- and FL-DCs 
obtained from hDEC transgenic mice were incubated with anti-hDEC-OVA. CD86, 
MHCI and MHCII expression by GM- and FL-DCs was equal to or higher than spleen 
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DCs (Fig. 16). But GM-DCs accumulated more OVA than spleen DCs or FL-DCs after 
anti-hDEC-OVA targeting (Fig. 13A, right). Nevertheless, GM-DCs were less effective 
than spleen DCs in cross-presentation (Fig. 13B, right). Consistent with their high levels 
of MHCII expression, GM-DCs were efficient in presenting pulsed peptides to MHCII 
restricted T cells (Fig. 13C, right). However, the same cells were intermediate, between 
CD8+ and CD8- DCs, for MHCII presentation after antigen capture by receptor-mediated 
endocytosis (Fig. 13B, right).  
 
FL-DCs were separated into CD8- (SIRPαhi) and CD8+ (CD24hi) subsets. Both FL-DC 
subsets induced less OTI proliferation than splenic DCs (Fig. 13 B, right). But FL-CD8+ 
DCs were also almost 10-fold less efficient than their splenic counterparts for MHCI 
presentation after exogenous peptide loading (Fig. 13 C, right). For MHCII presentation 
FL-CD8- DCs were more effective that FL-CD8+ DCs, the latter showing similar 
efficiency as their splenic counterpart CD8+ DCs (Fig. 13 B, right). Thus, both GM- and 
FL-DCs are capable of MHCI and MHCII presentation when antigen is captured by 
receptor-mediated endocytosis; however, these cells are less active than conventional 
spleen DCs.  
 
In order to determine how activation by TLR ligation alters DCs ability to present 
antigens acquired through receptor-mediated endocytosis, GM- or FL-DCs were 
stimulated with LPS and antigen presentation was assessed after targeting with anti-
mouse-DEC-OVA. Naïve splenic CD8+ DCs and LPS/IL-4 activated B cells were used as 
controls. As expected, stimulation with LPS enhanced expression of co-stimulatory 
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molecules, MHCI and MHCII in all culture-derived DCs (Fig. 16) (Trombetta and 
Mellman, 2005). GM-DCs activated with LPS expressed high levels of DEC-205 and 
thus captured 5-fold more antigen than any of the other DCs tested (Fig. 13D). In 
addition, when loaded with exogenous peptide, LPS-GM-DCs performed better than 
control CD8+ DCs in activating MHCI and MHCII-dependent T cell responses (Fig. 
13F). But, LPS-GM-DCs were far less effective than CD8+ DCs and no better than 
resting GM-DCs in cross-presentation of antigens acquired by receptor-mediated 
endocytosis (Fig. 13E). Finally, LPS stimulation also decreased the relative efficiency of 
GM-DCs with regards to processing antigen to be presented on MHCII (Fig. 13E).  
 
LPS-FL-DCs captured similar amounts of antigen as did control splenic CD8+ DCs (Fig. 
13D) but showed increased activation of MHCI and MHCII restricted T cells after 
peptide loading (Fig. 13F). Surprisingly, LPS stimulation had a positive impact on 
antigen presentation on FL-CD8+ but not on FL-CD8- DCs (Fig. 13D and E). In 
conclusion, when antigens were captured by receptor-mediated endocytosis, LPS failed to 
enhance MHCI and MHCII presentation by all cultured DCs, with the exception of FL-
CD8+ DCs. 
 
LPS/IL-4 activated B cells, which were used as an additional control, expressed higher 
levels of CD86, MHCI and MHCII than splenic DCs (Fig. 16), captured more antigen 
than CD8+ DCs (Fig. 13D) and were equivalent to CD8+ DCs in presenting exogenously 
loaded peptide to MHCI and MHCII restricted T cells (Fig. 13F). Consistent with these 
observations, activated B cells were also similar to CD8+ DCs in antigen presentation to 
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MHCII restricted T cells after antigen targeting to DEC-205 (Fig. 13E). On the other 
hand, B cell blasts induced far less OTI proliferation and were much less efficient than 
DCs in cross-presentation (Fig. 13E).  
 
In conclusion, when antigen is captured by receptor-mediated endocytosis, FL-DCs (both 
CD8+ and CD8-) resemble conventional spleen DCs with regards to efficiency of antigen 
presentation. Furthermore, antigen delivery by endocytosis through DEC-205 is not 
sufficient to ensure highly efficient cross-presentation, since B cells and LPS-GM-DCs 
were almost 10-fold less effective in cross-presentation than DCs. 
 
To determine whether the observed differences in antigen presentation were cell intrinsic 
or dependent on the route of antigen capture, cells were loaded with antigen by 
pinocytosis, using high concentrations of soluble OVA. In those experiments, OVA-
biotin was used to facilitate the measurement of antigen uptake. Although some 
preparations of OVA display mannose residues that serve as ligands for mannose 
receptors, there was no detectable binding of OVA to any of the cell types tested.  
 
Both splenic DC subsets obtained from naïve and immunized mice showed similar levels 
of OVA endocytosis (Fig. 17A, left). Despite their similarities in antigen uptake by 
endocytosis and presentation of exogenous peptides, OVA captured by bulk pinocytosis 
was presented far more effectively by CD8- than CD8+ DCs to MHCII restricted T cells 
(Fig. 17B and C, left). In addition, DCs obtained from immunized mice were more 
efficient at MHCII antigen presentation than naïve DCs, but the differences between the 
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subsets did not change qualitatively (Fig. 17B, left). Therefore, CD8- DCs are more 
efficient than CD8+ DCs at presentation to MHCII restricted T cells, irrespective of the 
route of antigen uptake or activation status.  
 
Despite antigen uptake at levels similar to conventional DCs, activated monocytes 
showed low levels of MHCII presentation of pinocytosed antigen, which correlated with 
low levels of presentation with pulsed peptide (Fig. 17, left). Yet, activated monocytes 
were similar to spleen DCs for cross-presentation (Fig. 17B, left). Thus activated 
monocytes can cross-present pinocytosed antigens as efficiently as spleen DCs; 
nevertheless, these cells are far less effective in MHCII presentation. 
 
Among cultured DCs, FL-DCs acquired similar amounts of OVA by pinocytosis as their 
spleen DC counterparts (Fig. 17A, right). Whereas FL-CD8- DCs were equivalent to 
spleen DCs for cross-presentation and more efficient with regards to MHCII presentation 
of pinocytized antigen, FL-CD8+ DCs were less effective in both tasks (Fig. 17B, right). 
GM-DCs accumulated similar amounts of OVA by bulk phase pinocytosis and performed 
similarly to CD8+ DCs for cross-presentation and intermediate between the two DC 
subsets for MHCII presentation (Fig. 17A and B, right).  
 
In contrast, activated B cells, which were active in endocytosis and presentation of 
peptides, were nearly inactive in processing antigen acquired by bulk phase pinocytosis 
for presentation on MHCII or MHCI (Fig. 17, right). Therefore, both the cell type and the 
route of endocytosis influence the efficiency of antigen presentation.  








Figure 17. Antigen presentation after pinocytosis in vitro. APCs were isolated from 
spleen or derived from bone marrow of WT mice. (A) The Y-axis shows relative cell-
associated OVA, developed with streptavidin-HRP, after incubation of the APCs with the 
indicated concentrations of OVA-biotin on the X-axis. (B) Activation and proliferation of 
OTI T cells (upper panels) and OTII T cells (lower panels) in response to OVA 
containing APCs. The Y-axis shows percentage of divided T cells. (C) Graphs show OTI 
(upper panels) and OTII (lower panels) proliferation in response to peptide pulsed APCs. 
Graphs represent pooled data from 3-5 independent experiments.  
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Figure 17
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To further analyze the effects of the route of antigen uptake on antigen presentation, 
OVA was delivered to antigen-presenting cells by phagocytosis of OVA-adsorbed  
polystyrene beads. Flow cytometry was used to purify cells that had captured a single 
fluorescent bead to normalize the amount of antigen captured. Internalization was 
confirmed by analysis on Image Stream cytometry (Fig. 18A), which combines flow 
cytometry with imaging of individual cells. Naïve and activated splenic DCs presented 
antigen acquired by phagocytosis in a manner that was similar to antigen captured by 
receptor-mediated or bulk phase pinocytosis (Fig. 18B). CD8- DCs remained more 
efficient than CD8+ in MHCII presentation, and cross-presentation was similar in both 
types of DCs (Fig. 18B and C). Decreasing the amount of OVA on the beads did not alter 
the results (Fig. 18C). However, neither activated monocytes nor GM-DCs, nor LPS 
activated GM-DCs presented phagocytized antigens to MHCI or MHCII restricted T cells 
to any appreciable degree (Fig. 18B). Similar results were obtained when splenic 
monocytes from Listeria infected mice were assayed (tip-DCs) (Fig. 19). In conclusion, 
activated monocytes and GM-DCs are far less effective in antigen presentation than 
conventional DCs when the antigen is acquired by phagocytosis. 




Figure 18. Antigen presentation after phagocytosis. APCs were isolated from spleen 
of naïve or mBSA-CFA immunized mice. GM-DCs were derived from bone marrow. 
Enriched populations were incubated with OVA-beads before sorting. APCs that had 
captured one OVA-bead were sorted. A, After sorting, cells were stained on ice with 
CD11c-, CD11b-, CD8- and MHCII-biotin, followed by streptavidin Pacific blue and 
analyzed on Image Stream 100 (Amnis). Histograms show distribution of internalization 
scores for the different APC populations, where positive scores indicate internalization. 
The percentage of cells with internalized beads is shown in each histogram and 4 
representative cell images are shown on the right. Representative images from cells that 
had a negative internalization score are also shown (lower images). B, Activation and 
proliferation of OTI T cells (left panel) and OTII T cells (right panel) after incubation 
with the number of APCs indicated in the X-axis, which were sorted to contain a single 
OVA-bead. The Y-axis shows percentage of divided T cells. C, as in B, but DCs from 
naïve mice were also incubated with beads adsorbed with 25% OVA and 75% KLH 
protein. B and C represent pooled data from 2-4 independent experiments. 
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Figure 18
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Figure 19. Comparison of tip-DCs elicited by Listeria monocytogenes infection and 
activated monocytes elicited by mBSA-CFA immunization. WT mice were 
immunized with mBSA-CFA and i.p. challenged with mBSA 24 hours before analysis. 
Alternatively, WT mice were infected with 3,000 Listeria monocytogenes i.v. and 
analyzed 48 hrs later. A, Representative flow cytometry profile of splenocytes (after 
exclusion of T cells, B cells, NK cells, granulocytes and pDCs) showing CD11c and 
CD11b expression (upper panels). Sorting scheme (lower panels), after further gating on 
CD11b+ CD8- cells, for CD8- DCs, activated monocytes (CD11c+ monocytes from 
immunized mice; iMono CFA), or tip-DCs (monocytes from Listeria infected mice; 
iMono Listeria). B, Representative dot-plots show expression of CD11b, CD11c, CD115 
(M-CSF receptor) and MHCII on CD8+ DCs, CD8- DCs, monocytes and CD11c+ 
monocytes. C, Representative histograms show CD86, MHCI and MHCII expression on 
the indicated cell populations. D, DCs (CD8+ and CD8-) were isolated from spleen of 
naïve mice and iMono from mBSA-CFA immunized mice (CD11c+ monocytes) or 
Listeria infected mice. Enriched populations were incubated with OVA-beads before 
sorting. Activation and proliferation of OTI T cells (top panel) and OTII T cells (lower 
panel) after incubation with the number of APCs indicated in the X-axis, which were 
sorted to contain a single OVA-bead or more than 2 beads, as indicated. The Y-axis 
shows percentage of divided T cells. E, as in D, but cells that did not capture any beads 
were sorted. 5x103 APCs were pulsed with the indicated concentrations of peptides in the 
X-axis and subsequently co-cultured with OTI (top panel) or OTII (lower panel) T cells. 
The Y-axis shows percentage of divided T cells. 
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Figure 19





Ralph M. Steinman and Zanvil A. Cohn first described dendritic cells in 1973 (Steinman 
and Cohn, 1973), and the new cells were characterized by their morphology and 
excellence at inducing mixed leukocyte reactions (Steinman and Witmer, 1978). It took 
many years and compelling evidence to convince the scientific community that DCs were 
distinct from macrophages. The main function of DCs is to present antigen to T cells, 
controlling both tolerance and immunity. However, there is still no single morphologic 
feature, function or unique expressed protein that can unambiguously identify DCs. For 
example, CD11c expression is key for identifying murine DCs, but it is also abundant in 
alveolar macrophages.  
 
Identifying unique genes required for DC development or for specifying DC functions is 
crucial. Using gene expression data from DCs, DC-progenitors and monocytes, our lab 
has identified candidate genes that may provide unique markers for the DC lineage, 
conserved in mice and humans. This information is necessary to resolve the monocyte, 
macrophage and DC definition controversy that still persists (Geissmann et al., 2010) and 
will help in settling the classification of myeloid cells. 
 
Elegant work has shown that DCs derive from unique progenitors that are distinct from 
monocytes and macrophages (Liu et al., 2009; Naik et al., 2007; Onai et al., 2007). 
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Therefore a DC identity based on ontogeny can be defined, at least in the steady state. 
During inflammation, monocytes differentiate into cells that have several features of DCs 
(CD11c and MHCII expression) (Serbina et al., 2008), but their role in eliciting immunity 
by antigen presentation is not well defined. Antigen presentation to T cells is the main 
function attributed to DCs, while monocytes and macrophages have a prominent role in 
the inflammation process and catabolism.  
 
In this thesis I explore antigen presentation by DCs and other antigen presenting cells. I 
find that although other antigen presenting cells, such as activated monocytes can present 
antigen, they are less efficient than DCs. Also, the route of antigen uptake has a profound 
impact on their ability to process antigen for MHC presentation. DCs derived from pre-
DCs present antigens irrespective of the route of antigen capture. Importantly, I also find 
differences for MHCII presentation between DC subsets. Thus I identify both unifying 
functional features for DCs and a division of labor among different subsets, based on 
antigen presentation. 
 
Early in the history of DCs it was observed that different subsets co-existed in lymphoid 
organs (Crowley et al., 1989). However, many of the molecules differentially expressed 
by DC subsets do not appear to confer a specialized function. Comparison of DCs from 
WT mice and mice deficient for CD8α (Kronin et al., 1997) or DEC-205 (Iyoda, 2002; 
data not shown) - two proteins widely used to define DC subsets - failed to show these 
molecules playing a role in DC development or T cell activation. Yet the advent of new 
technologies and further characterization of DC subsets, comparing global gene 
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expression (Dudziak et al., 2007; Edwards et al., 2003a; Robbins et al., 2008), 
definitively showed that distinct subsets are related but unique. For example CD8+ and 
CD8- DCs differ in expression of C-type lectins (Dudziak et al., 2007) and TLRs 
(Edwards et al., 2003b). Thus each DC subset displays unique abilities to bind and 
respond to different pathogens. 
 
Here I have addressed differences between splenic CD8+ and CD8- DCs in antigen 
processing and presentation.  Previous studies have shown that cell-associated antigens 
are cross-presented by CD8+ DCs (den Haan et al., 2000; Hildner et al., 2008; Schulz and 
Reis e Sousa, 2002), which can be attributed to their higher ability to capture dead cells 
(Iyoda et al., 2002; Schulz and Reis e Sousa, 2002). Both CD8+ and CD8- DCs cross-
present antigens expressed by bacteria (Schulz and Reis e Sousa, 2002; Yrlid and Wick, 
2002). When soluble antigen is administrated to mice, it has been shown that CD8+ DCs 
are better at cross-presentation, while CD8- DCs are better at MHCII presentation 
(Pooley et al., 2001; Schnorrer et al., 2006). However, a careful analysis of antigen 
uptake shows that CD8+ DCs may actually capture more soluble antigen than CD8- DCs 
(Idoyaga et al., 2009; Pooley et al., 2001; Schnorrer et al., 2006). Likewise, many reports 
failed to ensure that both DC subsets had equal access to antigen (Belz et al., 2005) or 
used the same mechanism for antigen internalization, precluding conclusions on the 
antigen presentation efficiency of DC subsets.  
 
The advent of recombinant antibodies carrying antigen that bind to DC receptors enabled 
comparison between different DC subsets and receptors. Transgenic mice expressing 
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human DEC-205 molecules driven by the CD11c promoter, provided expression of a 
shared receptor on distinct DC subsets. In addition, previous work with anti-DEC antigen 
targeting validated this antigen delivery strategy for MHC presentation, without affecting 
DC maturation (Bonifaz et al., 2002; Bonifaz et al., 2004; Hawiger et al., 2001; Hawiger 
et al., 2004).  
 
Using anti-hDEC chimeric antibodies carrying antigen to both CD8+ and CD8- splenic 
DCs, I show that CD8- DCs excel at MHCII presentation. This feature correlates with 
higher expression of some cathepsins and other antigen processing enzymes, as well as 
lower expression of cystatin C (a cathepsin inhibitor) (Dudziak et al., 2007). The 
superiority of CD8- DCs over CD8+ DCs for MHCII presentation was evident 
independent of the mouse strain (C57BL/6, B10.BR or C3H/HeJ), antigen (HEL or 
OVA) and inflammatory context (with or without co-administration of LPS or anti-
CD40) (Fig. 2, 3, 4 and 5). Moreover, CD8- DCs excel at MHCII presentation whether 
the antigen is internalized by receptor-mediated endocytosis, pinocytosis or phagocytosis 
(Fig. 13, 17 and 18).  
 
DCs present antigens efficiently in the steady state.  Although DC activation can improve 
subsequent T cell activation, TLR ligation is not necessary for antigen presentation (Fig. 
3 and 4). Interestingly, upon activation, CD8+ DCs improve their ability to activate 
antigen-specific CD4+ T cells (Fig. 4, 13 and 17). Therefore CD8+ DCs might also have 
an important and unique role in activating CD4+ T cells in mice undergoing 
inflammation. The class of effector helper T cells elicited is modulated by the antigen 
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presenting cell, and CD8+ DCs are known for Th1 polarization (Maldonado-Lopez et al., 
1999; Maldonado-Lopez et al., 2001; Soares et al., 2007).  
 
DCs have an intricate relationship with regulatory T cells. There is a feedback regulatory 
loop between DCs and regulatory T cells: an increase in DC numbers also increases 
proliferation of regulatory T cells and depletion of DCs diminishes regulatory T cells 
(Darrasse-Jeze et al., 2009), but depletion of regulatory T cells increases DC proliferation 
(Kim et al., 2007) through a FL-dependent mechanism (Liu et al., 2009). Distinct DC 
subsets have unique features that can affect their interaction with regulatory T cells. 
Consistent with their higher MHCII presentation ability, CD8- DCs are better at 
promoting regulatory T cell division. However antigen presentation by CD8+ DCs can 
convert naïve T cells into regulatory T cells by a TGF-β dependent mechanism 
(Yamazaki et al., 2008). 
 
With regards to cross-presentation, my data shows that when the amount of antigen 
captured and the route of internalization are taken into consideration, the two subsets of 
conventional spleen DCs have similar abilities. When I compared CD8+ and CD8- DCs 
for cross-presentation following anti-hDEC targeting, I found that both subsets are 
equally able to cross-present antigens to CD8+ T cells (Fig. 7 and 13). In agreement with 
others, there were small differences in MHCI cross-presentation by the two DC subsets in 
some instances: CD8+ DCs were slightly more efficient than CD8- DCs, after 
phagocytosis of OVA-adsorbed beads or soluble antigen (Schnorrer et al., 2006), and also 
after receptor-mediated endocytosis when limiting number of DCs are compared (Fig. 17, 
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18 and 14). However, these differences between CD8+ and CD8- DCs were far less 
pronounced than the difference between either subset of DCs and other antigen 
presenting cells. Therefore it seems unlikely that CD8+ DCs possess a specialized cellular 
machinery that facilitates antigen cross-presentation; given access to antigen, CD8- DCs 
are also very efficient at MHCI cross-presentation. 
 
Cross-presentation of cell-associated antigens is important for generating cytotoxic T 
cells to control viral infections and tumor growth. CD8+ DCs are very efficient to capture 
dying cells (Iyoda et al., 2002) and this feature enable access to a huge and important 
source of antigens. Hence, mice deficient in the transcription factor Batf3, which lack 
CD8+ DCs, have reduced CD8+ T cell responses to West Nile virus and impaired tumor 
rejection (Hildner et al., 2008).  
 
After antigen targeting to DCs, MHCI presentation lasted for 10 days and MHCII 
presentation for 5 days (Fig. 2). The difference between MHCI and MHCII is probably 
due to the distinct sensitivity of the transgenic cells used to detect MHC-pep complexes: 
OTI cells are more sensitive than OTII cells. Long lasting antigen presentation is most 
likely sustained by a high initial antigen load and is consistent with DC proliferation and 
the ability of daughter cells to present MHC-pep complexes from progenitors, as well as 
the replacement kinetics of splenic DCs (10-14 d) (Liu et al., 2007).  
 
Splenic CD8- DCs can be further subdivided into CD4+ and CD4- DCs; however both are 
phenotypically and functionally similar and regarded as a single group (Edwards et al., 
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2003a). In most experiments performed for this thesis, when isolating CD8- DCs I also 
sorted for CD4+ cells in order to enrich for DCIR2+ cells and avoid inclusion of potential 
DC progenitors. Moreover one must ensure that other non-DCs that express CD11c are 
not isolated in the CD8- DC pool. For example, activated Ly6C+ monocytes upregulate 
CD11c; therefore in inflammatory settings inclusion of the Ly6C marker is imperative for 
separating bona fide CD8- DCs from activated monocytes. In a recent report it was shown 
that upon inflammation in the gut, monocytes differentiate into CD11c+ cells that express 
E-cadherin; thus this molecule might also constitute a useful marker in future studies 
(Siddiqui et al., 2010). It is important to highlight that after viral infection, without proper 
gating strategies, NK cells might also be isolated together with CD8- DCs, resulting in 
erroneous diminishing conclusions on the antigen presentation potential of CD8- DCs 




Targeting antigen with anti-DCIR2 to CD8- DCs leads to poor cross-presentation, but 
anti-hDEC antigen targeting to the same cells results in efficient cross-presentation (Fig. 
7). This result might be explained by quantitative differences in the amount of antigen. 
Anti-DEC205 delivers more antigen to DCs than anti-DCIR2 (Fig. 7, 8C and results not 
shown). Supporting this concept, anti-hDEC targeting to CD8- DC elicits more MHCII 
presentation than anti-DCIR2 (Fig. 7B). Additionally, DCIR2 internalization is not 
efficient when compared to DEC-205 (Fig. 8 and 9).  
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In looking for another receptor that would efficiently internalize antigens, I turned to B 
cells. B cells possess a specialized receptor for antigen uptake (the BCR), and when 
activated, B cells can upregulate DEC-205 (Fig. 10). Therefore DEC-205 and BCR-
mediated antigen capture were compared for MHC presentation. DEC-205 was as 
effective as the BCR to promote antigen presentation onto MHCII; and DEC-205-
mediated antigen capture was more effective than the BCR to promote antigen cross-
presentation into MHCI molecules (Fig. 11).  
 
These results also illustrate that MHCI and MHCII presentation are independent: 
increasing cross-presentation does not necessarily lead to a decrease in MHCII 
presentation, and antigen internalization through different receptors can influence antigen 
processing and presentation. DEC-205 is a receptor that efficiently delivers antigens for 
both MHCI and MHCII presentation. 
 
Although DEC-205 was more efficient than the BCR to promote cross-presentation, 
activated B cells were significantly less efficient than DCs at cross-presentation (Fig. 13). 
Previous reports describing B cell cross-presentation did not compare them to bona fide 
DCs or accounted for the amount of antigen captured (Robson et al., 2008). Activated B 
cells were as effective as CD8+ DCs at MHCII presentation when the antigen was 
delivered by receptor-mediated endocytosis (DEC-205 or BCR), but the same cells were 
ineffective when the antigen enters the cell by bulk phase endocytosis.  
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As has been previously documented, antigen uptake was at least 100-fold more efficient 
when delivered through specific receptors as compared to bulk phase pinocytosis (Jiang 
et al., 1995). However, when equivalent amounts of ingested antigen are compared, the 
presentation efficiency of DCs was similar for bulk phase and receptor-mediated 
endocytosis (Fig. 13 and 17). B cells differed from DCs in that antigens internalized by 
pinocytosis were presented very inefficiently when compared to receptor-mediated 
uptake (Fig. 17). Unlike DCs, whose primary function is to initiate immunity, B cells 
present antigens to recruit specific cognate T cell help. The relative inefficiency at 
processing and presentation of antigens acquired by bulk phase endocytosis guarantees 
that T cell help remains focused during an immune response. The B cell receptor is 
highly efficient at capturing cognate antigens for presentation to T cells (Rock et al., 
1984), and thus, only B cells that capture antigen through specific antigen receptors will 
recruit T cell help. In contrast, the DCs’ ability to present a range of antigens acquired by 
pinocytosis serves to broaden the scope of T cell immunity. 
 
DEC-205 might facilitate cross-presentation due to its intracellular trafficking. DEC-205 
and MMR are in the same family of C-type lectins (Jiang et al., 1995), and MMR-
mediated antigen capture promotes cross-presentation by retaining antigen in early 
endosomal compartments (Burgdorf et al., 2007). However, DEC-205 and MMR differ in 
intracellular localization: contrary to the MMR, most DEC-205 co-localizes with Lamp-1 
and MHCII positive compartments, and DEC-mediated antigen internalization promotes 
MHCII presentation in immature GM-DCs (Mahnke et al., 2000).  
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Mahnke et al. have explored DEC-205 intracellular trafficking, trying to identify amino 
acid residues in the cytoplasmic tail that guide sorting (Mahnke et al., 2000). MHCII+ 
fibroblasts were transfected with chimeric receptors bearing the external domain CD16 
(FcγRIII) fused to the cytosolic tail of MMR or DEC-205. In addition to the wild type 
sequence, DEC-205 receptors bearing truncations and mutations in the cytoplasmic tail 
were also analyzed in this heterologous system. The authors show that truncated DEC-
205 cytoplasmic tails lacking the residues “FSSVRY” have a defect in internalization that 
impairs antigen presentation. On the other hand, truncated DEC-205 cytoplasmic tails 
lacking the residues “EDE”, or substitution of those residues for alanines, have normal 
internalization; yet intracellular DEC-205 delivery into Lamp-1+ compartments and 
MHCII antigen presentation are both impaired (Mahnke et al., 2000). In this system 
cross-presentation was not addressed (Mahnke et al., 2000). 
 
Based on the above findings, I was interested in assessing whether particular amino acid 
residues in DEC-205 cytoplasmic tail sequences might control access to “cross-
presentation permissive compartments”. In my analysis I used DEC-205 bearing similar 
cytoplasmic tail truncations and mutations as Mahnke et al. (Table 1). However I 
transduced the full receptor into activated B cells and performed antigen targeting with 
chimeric monoclonal anti-DEC-OVA for analysis of both MHCI and MHCII 
presentation.  
 
In accordance with previous results, I also found that a DEC-205 receptor bearing a short 
cytoplasmic tail missing the “FSSVRY” motif (DEC-short) was defective in 
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internalization. However it only had a minor impact on antigen presentation (Fig. 12A). 
This can be attributed to the protocol used for antigen administration: anti-DEC-OVA 
was added to B cells on ice and excess antigen washed before incubation at 37°C. When I 
performed similar experiments where anti-DEC-OVA was administered for 2 hours at 
37°C, the difference between DEC-WT and DEC–short was much more dramatic (results 
not shown): DEC-WT can recycle, thus antigen administration at 37°C enables more 
antigen capture than antigen administration on ice. Even though DEC-short receptors are 
severely impaired in internalization, over time some antigen is internalized, and it proved 
to be enough to allow for antigen presentation onto both MHCI and MHCII.  
 
All other DEC-205 receptors bearing cytoplasmic truncations or mutations into alanines 
had an identical behavior as DEC-WT for MHCII presentation and cross-presentation 
(Fig. 12). It is hard to reconcile this observation with the conclusions drawn by Mahnke 
et al., which defined the importance of the cytoplasmic tri-acidic cluster “EDE” in 
promoting MHCII presentation. It is possible that in B cells (and other antigen presenting 
cells expressing DEC-205), the DEC-205 transmembrane or the extracellular domain 
associate with other proteins that dictate intracellular sorting. Alternatively, since I used a 
different DEC-205 ligand (I used a monoclonal antibody and Mahnke et al. used 
polyclonal antibodies), the antigen might dissociate from the DEC-205 receptor in 
endosomes bearing different characteristics, thus presenting distinct susceptibility to 
antigen processing and presentation. In conclusion, I could not identify amino acid 
residues in the cytoplasmic tail of DEC-205 to account for intracellular sorting into 
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antigen presentation compartments. In my experiments, the main factor affecting antigen 
presentation was amount of antigen internalized. 
 
The recycling properties of DEC-205 constitute an advantage that increases antigen 
capture and consequently antigen presentation. This advantage was observed when 
antigen was administered at 37°C to activated B cells, as discussed above. Similar 
differences were also observed between DEC-205 and the BCR: when anti-DEC-OVA 
and NP-OVA where given for 2 hours at 37°C to NP-specific activated B (similar to Fig. 
11), DEC-205 promoted higher antigen capture and presentation than the BCR, since the 
BCR does not recycle (results not shown). These observations are important and should 
also be taken into consideration when comparing anti-DEC targeting to anti-DCIR2 
targeting in vivo, since DCIR2 does not recycle (results not shown). In conclusion, 
recycling provides another advantage of DEC-205 over DCIR2 for antigen delivery 
 
 
Comparing other APCs to bona fide DCs 
Besides DCs, other cell types, such as liver endothelial cells (Limmer et al., 2000) and 
macrophages (Kovacsovics-Bankowski et al., 1993; Rock et al., 1993), have been 
reported to cross-present antigens. However a direct comparison between other cell types 
and DCs, where the amount of antigen internalized is also taken into account, was 
lacking. 
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Monocytes develop in the bone marrow and circulate in the blood. The spleen constitutes 
a reservoir for rapid deployment during inflammation (Swirski et al., 2009). Two subsets 
can be identified: Ly6Chi monocytes (CD11b+ CCR2+ CD62L+ CX3CR1low) and Ly6Clo 
monocytes (CD11b+ CCR2- CD62L- CX3CR1high). The differential expression of 
chemokine receptors determines their recruitment and might impact function. In the 
steady state monocytes are precursors of numerous populations of tissue macrophages: 
liver Kupffer cells, splenic marginal zone and red pulp macrophages, lung alveolar 
macrophages and microglial cells in the central nervous system. In the steady state, 
monocytes do not significantly contribute to the pool of DCs in lymphoid organs (Liu et 
al., 2009) and may only contribute to CD103- populations of CD11c+ cells in non-
lymphoid organs (Bogunovic et al., 2009; Varol et al., 2009), which have poor T cell 
stimulation capacity (Bogunovic et al., 2009; Schulz et al., 2009). Monocytes are 
endowed with great plasticity, and during inflammation, activated monocytes can also 
differentiate into cells with similar features as DCs.  For example, during Listeria 
infection, the spleen is infiltrated by short-lived CD11c+ MHCII+ monocyte-derived cells 
that secrete TNF-α and NO (tip-DCs), which are important for innate bacterial clearing 
(Serbina et al., 2003). Yet activated CD11c+ monocytes do not express characteristic DC 
lectins (DCIR2 or DEC-205) or high levels of Flk2 (FL receptor), but instead express the 
M-CSF receptor like their monocyte progenitors (Fig. 15 and 19).  
 
Activated monocytes contribute to immunity against several pathogens, such as influenza 
(Nakano et al., 2009), Toxoplasma (Robben et al., 2005) Lesihmania (Leon et al., 2007) 
and Listeria (Serbina et al., 2003). However activated monocytes do not appear to be 
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responsible for the initiation of adaptive immune responses (Serbina et al., 2003). This is 
consistent with these cells’ lower level of MHCII expression (Fig. 15, 16 and 19) and 
their poor performance in MHCII presentation (Fig. 13, 17 and 18), irrespective of the 
mechanism of antigen capture, including peptide pulsing.  
 
Activated monocytes can efficiently cross-present antigens captured through DEC-205 or 
pinocytosis, but not phagocytized antigens (Fig. 13, 17 and 18). Similar results were 
obtained with GM-DCs, suggesting that even though monocyte-derived cells can cross-
present antigens, they might rely on different mechanisms than bona fide DCs. A recent 
report has shown, for example, that activated monocytes, unlike CD8+ DCs, depend on 
insulin-regulated aminopeptidase (IRAP) in early endosomes to trim peptides for MHCI 
loading and cross-presentation (Segura et al., 2009).  
 
A possible role of monocyte-derived cells in T cell responses is a matter of debate. 
Monocyte-derived cells have been shown to contribute to T cell immunity during 
Leishmania infection (Leon et al., 2007) and Aspergillus fumigatus lung infection (Hohl 
et al., 2009), as well as Th1 polarization in both influenza infection and CFA 
immunization (Nakano et al., 2009). However, formal proof showing efficient antigen 
processing and presentation by monocyte-derived cells is still lacking. Inflammatory 
reactions involve the orchestrated recruitment and activation of different cell types. 
Therefore the use of CCR2-deficient mice, which have impaired monocyte emigration 
from the bone marrow, or monocyte depletion systems are not ideal for studying specific 
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functions carried out by monocytes. Lack of monocyte-derived cells might, for example, 
impair DC activation or antigen transport to lymph nodes (Ravindran et al., 2007).  
 
Monocytes can undergo distinct activation programs and differentiation, depending on 
the stimuli, and thereby acquire different functions. Cells similar to tip-DCs also occur 
naturally in the lamina propria of naïve mice, in response to commensal bacteria, where 
they induce IgA class switching (Tezuka et al., 2007). Monocytes plasticity has been well 
explored by in vitro systems: whereas addition of M-CSF triggers macrophage-like 
differentiation, GM-CSF promotes a DC-like differentiation program, generating CD11c+ 
cells. In the CFA immunization model, activation of monocytes is dependent on GM-CSF 
signaling (Fig. 15), but in Listeria infection, tip-DC differentiation is independent of GM-
CSF signaling (results not shown) and triggered by IFN-γ production by NK cells (Kang 
et al., 2008). Yet both activated monocytes from immunized mice and tip-DCs from 
Listeria infected mice were poor at CD4+ T cell activation and at cross-presentation of 
phagocytized antigens (Fig. 19). Nevertheless, due to the notable plasticity of 
hematopoietic cells, it is still conceivable that, given the right cues (e.g. cytokines), 
monocytes might differentiate into cells that are efficient at T cell activation. 
 
Although they appear to be most closely related to activated monocytes and tip-DCs 
(Robbins et al., 2008; Xu et al., 2007), the physiologic counterparts of GM-DCs remain 
to be defined. Similarly to in vivo activated monocytes, GM-DCs can present antigens 
captured by receptor-mediated or bulk phase pinocytosis but are far less efficient in 
presenting phagocytized antigen than conventional DCs (Fig 13, 17 and 18). This 
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observation is consistent with the finding that mononuclear phagocytes tend to have more 
developed lysosomes that may hamper the escape of processed peptides into MHC 
loading compartments (Ehrenreich and Cohn, 1967; Savina and Amigorena, 2007). 
Macrophages are highly phagocytic, and it was estimated that OVA bound to 2-3 µm 
diameter beads is cross-presented 1,000 to 10,000-fold more efficiently than soluble 
antigen (Kovacsovics-Bankowski et al., 1993). However this comparison was based on 
the concentration of antigen incubated with macrophages and not the actual amount of 
captured antigen. Red pulp macrophages are more active than splenic DCs for 
phagocytosis after intravenous administration of polysterene beads, Escherichia coli or 
Staphylococcus aureus (Idoyaga et al., 2009). Likewise, GM-DCs and activated 
monocytes were more phagocytic than splenic DCs: a higher percentage of cells captured 
beads and also more beads were taken up per cell (results not shown). Therefore, the 
primary function of activated monocytes and GM-DCs might be as innate immune 
effector cells, like neutrophils and macrophages, which destroy most phagocytized 
antigen (Serbina et al., 2003; Soehnlein and Lindbom, 2010; Xu et al., 2007). 
 
DCs transport MHCII to the cell surface after activation by TLR ligation (Inaba et al., 
2000; Pierre et al., 1997; Trombetta et al., 2003; Trombetta and Mellman, 2005). 
However GM-DCs prior activation did not have a positive impact on their ability to 
present antigens to T cells (Fig 13). In contrast, FL-DCs resembled conventional spleen 
DCs in this important respect; antigen presentation was enhanced by activation through 
TLR ligation: FL-CD8+ DCs performed poorly at antigen presentation without LPS 
activation (Fig. 13). Also, mirroring their splenic counterparts, FL-CD8- DCs were better 
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than FL-CD8+ DCs in activating MHCII restricted T cells (Fig 13 and 17). FL-DCs 
originate from the same progenitor (pre-DCs), rely on the same cytokine (FL) for 
differentiation and expansion, and are more similar to conventional DCs in antigen 
processing and presentation.  
 
The bone marrow provides a niche for the maintenance and differentiation of 
hematopoietic progenitor cells: cell-cell interactions and cell-extracellular-matrix 
contacts have an important role, in addition to various cytokines (Wilson and Trumpp, 
2006). Similarly, when DC progenitors arrive in peripheral lymphoid tissues and non-
lymphoid tissues, microenvironment cues guide final differentiation to generate different 
subsets. Given the complexity of the differentiation process, it is not surprising that in 
vitro cultures of progenitors with cytokine mixtures cannot reproduce the same 
developmental pathway occurring in vivo. Nevertheless, the ability to differentiate DC-
like cells in vitro from precursors is a very important tool for both basic studies and 
clinical applications. GM-DCs have a closer resemblance to activated monocytes and tip-
DCs; thus FL constitutes a better alternative to obtain dendritic cells from precursors. 
Fully understanding DC development, and dissecting signaling and transcriptional 
programs, will impact in the design of new strategies for in vitro differentiation of human 
DCs that will more closely resemble the cells present in different tissues in vivo.  
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Concluding remarks 
 
The division of dendritic cells into subsets is supported by functional specialization: I 
show here that splenic CD8- DCs excel at MHCII presentation. However no major 
differences between CD8+ and CD8- DCs with regards to cross-presentation were 
observed when the amount of antigen and route of uptake were taken into account.   
 
Cross-presentation onto MHCI molecules is not restricted to conventional DCs. In vivo 
activated monocytes, for example, were efficient at cross-presenting antigens captured by 
receptor-mediated endocytosis or pinocytosis. Yet the route of antigen uptake has a major 
impact on the ability of non-DCs to process antigen for MHC presentation: CD11c+ 
monocyte-derived cells, including GM-DCs, where far inefficient at processing 
phagocytized antigen for cross-presentation or MHCII presentation. Therefore DCs differ 
from all other cells tested in that they excel in antigen presentation irrespective of the 
route of antigen uptake. This observation is important when analyzing the role of 
monocyte-derived cells during inflammation. Moreover it has implications for the use of 
GM-DCs for antigen presentation to T cells. This study was limited to antigen 
presentation assays, but it would be valuable to extend it to also analyze the development 
of different classes of effector T cells. 
 
Expression of CD11c and MHCII is not sufficient to classify a cell as a DC and antigen 
presentation assays should be carefully performed to analyze relative efficiency. The 
                 115
amount of antigen captured is a major factor that influences the magnitude of antigen 
presentation and should be more carefully monitored.  
 
Expression of particular patterns in pathogens or antigen targeting to receptors provides 
antigen access to specific cell types. In vivo antigen delivery with anti-DEC antibodies is 
efficient for antigen presentation because it targets DCs and ensures internalization of 
high amounts of antigen. CD8- DEC- DCs are better at presenting antigen onto MHCII 
than CD8+ DEC+ DCs, however upon activation CD8+ DEC+ DCs increase their MHCII 
processing ability. Thus, when combined with appropriate maturation stimuli, anti-DEC 
antigen targeting provides an effective strategy to activate both CD8+ and CD4+ T cells. It 
would be desirable to identify other receptors that have similar features as DEC but are 
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